furosemide has been researched along with Chronic Illness in 200 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is a prospective randomized controlled trial to study the efficacy and safety of Shenfu injection combined with furosemide in the treatment of coronary heart disease and chronic heart failure." | 9.41 | Shenfu injection combined with furosemide in the treatment of chronic heart failure in patients with coronary heart disease: A protocol of randomized controlled trial. ( Gao, Y; Tan, X; Zhu, R, 2021) |
| "Aerosol furosemide may be an option to treat refractory dyspnea, though doses, methods of delivery, and outcomes have been variable." | 9.34 | Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients. ( Banzett, RB; Hallowell, RW; O'Donnell, CR; Schwartzstein, R; Sheridan, A, 2020) |
| "The aim of this study was to determine the diuretic effect of acetazolamide in patients with exacerbations of chronic heart failure, in addition to their stable diuretic therapy." | 9.24 | Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study. ( Budaj, A; Imiela, T, 2017) |
| " Patients in group 1 (125 mg furosemide) had a mean age of 77 ± 17 years, 43% were male, 6 (43%) had heart failure with a preserved ejection fraction (HFpEF), and 64% were in New York Heart Association (NYHA) class IV; the mean age of patients in group 2 (250 mg furosemide) was 80 ± 8." | 9.20 | Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure. ( Balistreri, F; Butler, J; Cuttitta, F; Di Gaudio, F; di Pasquale, P; Greco, M; Indelicato, S; La Rocca, V; Lupo, U; Parrinello, G; Paterna, S; Rizzo, G; Torres, D, 2015) |
| "Spironolactone, not furosemide, improved insulin resistance in CHF patients probably by the inhibition of inflammatory cytokines and MMPs." | 9.19 | Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure. ( Anker, SD; Doehner, W; Hisatome, I; Kato, M; Kinugasa, Y; Ogino, K; Yamamoto, K, 2014) |
| "Furosemide is the diuretic of choice for the treatment of hypertension in chronic kidney disease but the adaptative changes in the distal nephron may decrease its efficacy." | 9.16 | A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2012) |
| "The role of repeated infusions of Levosimendan (LEVO) in patients with chronic advanced heart failure is still unclear." | 9.16 | Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival. ( Branzi, G; Della Rosa, F; Facchini, M; Malfatto, G; Parati, G; Rella, V; Villani, A, 2012) |
| "The aim of this study was to evaluate the effects of both the prolonged-release (PR) formulation of torasemide (torasemide-PR) and furosemide on myocardial fibrosis in hypertensive patients with chronic HF." | 9.15 | Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. ( , 2011) |
| "Loop diuretics, such as torasemide and furosemide, are important agents in the treatment of chronic heart failure." | 9.14 | TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. ( Anguita, M; Castro-Beiras, A; Cobo, E; Coca, A; Conthe, P; de Teresa, E; Díez, J; Fernández, E, 2009) |
| "In patients with CHF, tolvaptan was well tolerated; it reduced body weight and edema and normalized serum sodium in the hyponatremic patients." | 9.10 | Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. ( Czerwiec, F; Gheorghiade, M; Kambayashi, J; Niazi, I; Orlandi, C; Ouyang, J; Zampino, M, 2003) |
| "The hypothesis was that torasemide, due to more predictable pharmacokinetics/pharmacodynamics, induces greater improvements in functional and social limitation than furosemide and reduces the frequency of hospitalisations in primary care patients with chronic heart failure (CHF)." | 9.10 | Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life. ( Gamba, G; Hess, B; Jaquet, F; Müller, K, 2003) |
| "Male patients with mild heart failure were randomly assigned to 9 days of therapy with 20 mg frusemide twice a day, 200 mg candoxatril twice a day, or 400 mg candoxatril twice a day (n = 10 per group) after a 14-day placebo washout phase." | 9.09 | Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. ( Dargie, HJ; Newby, DE; Norrie, J; Northridge, DB; Rooney, E, 1999) |
| "The study aimed to assess the hemodynamic and neuroendocrine effects of candoxatril and frusemide compared with placebo in patients with mild chronic heart failure." | 9.09 | Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. ( Bostrøm, P; Christensen, CC; Parikka, H; Rykke, EO; Toivonen, L; Westheim, AS, 1999) |
| "We sought to determine the effect of aspirin on the venodilator effect of furosemide in patients with chronic heart failure (CHF) BACKGROUND: Furosemide has an acute venodilator effect preceding its diuretic action, which is blocked by nonsteroidal anti-inflammatory, drugs." | 9.09 | Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. ( Davie, AP; Jhund, PS; McMurray, JJ, 2001) |
| "We studied the synergism between high-dose furosemide and hydrochlorothiazide in patients with severe congestive heart failure and impaired renal function showing diuretic resistance to a daily dose of furosemide of at least 250 mg." | 9.08 | Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. ( Dormans, TP; Gerlag, PG, 1996) |
| "This study examined the effects of conventional doses of oral captopril on the renal responses to oral furosemide in ambulant patients with stable chronic heart failure." | 9.07 | Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. ( Bridges, AB; Fraser, CG; McLay, JS; McMurray, JJ; Struthers, AD, 1993) |
| "To analyze the physical performance of the patients with congestive heart failure (CHF), grades I and II of the New York Heart Association (NYHA), submitted to ergometric test: 1) under conventional treatment with digitalis and diuretic; 2) with an angiotensin converting enzyme inhibitor, captopril, associate with conventional treatment; 3) using captopril associated with digitalis or diuretic." | 9.07 | [Captopril in the treatment of patients with congestive heart failure. Its bicycle ergometry evaluation]. ( Benchimol, C; Ferreira Filho, SR; Hatab, SA; Nascimento, LO; Saragoça, MA, 1992) |
| "To test the hypothesis that alternate-day administration of furosemide will result in a sustained improvement in pulmonary function without causing alterations in electrolyte or mineral homeostasis, we conducted a randomized, double-blind, placebo-controlled study of 11 hospitalized, oxygen-dependent, spontaneously breathing infants with chronic bronchopulmonary dysplasia." | 9.06 | Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. ( Engelhardt, B; Hazinski, TA; Parker, RA; Rush, MG, 1990) |
| "18 patients with II NYHA class chronic congestive heart failure (CCHF) had been given nifedipine (Cordipin) 54." | 9.06 | [Evaluation of the effect of nifedipine in patients with chronic congestive heart failure]. ( Bechler-Lisińska, J; Broks-Bratkowska, B; Cholewa, M; Dryjański, T; Gawor, Z; Górski, L; Markiewicz, K, 1989) |
| "Captopril alone as therapy for mild heart failure was compared with a combination of frusemide and amiloride in a double-blind randomised crossover trial in 14 patients who had previously been treated with diuretics." | 9.06 | Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. ( Bayliss, J; Parameshwar, J; Poole-Wilson, PA; Richardson, A; Scriven, AJ; Sutton, GC, 1987) |
| "Renal function and excretion of water, salt, and the prostacyclin hydration product (6-keto-PGF1 alpha) were evaluated in 10 furosemide-treated patients with well-controlled congestive heart failure." | 9.06 | Renal function and tubular transport effects of sulindac and naproxen in chronic heart failure. ( Beermann, B; Eriksson, LO; Kallner, M, 1987) |
| "The diuretic effects of torasemide and of furosemide were compared in a double blind cross-over study in 13 patients with stable chronic heart failure." | 9.06 | Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. ( Delarge, J; Luyckx, AS; Scheen, AJ; Vancrombreucq, JC, 1986) |
| "In an experimental heart failure model, we tested the hypothesis that furosemide causes excess mortality." | 7.78 | Furosemide induces mortality in a rat model of chronic heart failure. ( Anker, SD; Bauersachs, J; Bockmeyer, B; Doehner, W; Hocher, B; Rokutan, H; Springer, J; Strassburg, S; Suckow, C; von Haehling, S; von Websky, K; Waller, C, 2012) |
| "The effect of enalapril, digoxin and frusemide combination on clinical, biochemical and anthropometric indices were determined in eight cachectic Nigerians with chronic congestive heart failure [body mass index (BMI) 20." | 7.71 | The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. ( Adigun, AQ; Ajayi, AA, 2001) |
| "We studied the effects of inhaled furosemide (40 mg) on bronchial responsiveness to acetylcholine (ACh) in patients with chronic congestive heart failure who had been premedicated with indomethacin (75 mg/day) for five days." | 7.69 | [Effects of inhaled furosemide after indomethacin premedication on bronchial hyperresponsiveness in patients with chronic congestive heart failure]. ( Ishizaki, T; Kanamori, K; Mifune, J; Miyabo, S; Nakai, T; Saitoh, Y; Sakai, T; Sasaki, F, 1994) |
| "We studied the effects of inhaled and intravenous furosemide (40 mg) on bronchial responsiveness to acetylcholine (ACh) in patients with chronic congestive heart failure." | 7.68 | [Effects of inhaled and intravenous furosemide on bronchial hyperresponsiveness in patients with chronic congestive heart failure]. ( Fujimura, M; Hifumi, S; Ishizaki, T; Mifune, J; Miyabo, S; Nakai, T; Sakai, T; Sasaki, F; Takahashi, H, 1992) |
| "1 yrs) with III or IV NYHa class congestive heart failure after 2-week therapy with digoxin (D) and furosemide (F) underwent two-dimensional echocardiographic examination to assess left ventricular function." | 7.68 | [Changes in left-ventricular function in chronic congestive heart failure treated with digoxin, furosemide and vasodilators]. ( Cholewa, M; Dryjański, T; Gawor, Z; Markiewicz, K, 1990) |
| " Rats were divided into four groups as follows: normokalemic control (group I, n = 10), acute hypokalemia with furosemide (group II, n = 16), acute hypokalemia with hyperventilation (group III, n = 18), and chronic hypokalemia induced by a low potassium (K+) diet (group IV, n = 22)." | 7.67 | Hypokalemia in rats produces resistance to dysrhythmias under halothane anesthesia. ( Farina, JP; Kwon, NJ; Stolte, AL, 1989) |
| "The data on protein excretion with urine under the effect of furosemide were compared clinically and morphologically with the morphological signs of tubulostromal lesions in the kidneys in 19 patients suffering from amyloid nephropathy and in 33 patients with chronic glomerulonephritis." | 7.67 | [Effect of furosemide on proteinuria in patients suffering from amyloidosis and chronic nephritis with various tubulostromal lesions of the kidneys]. ( Pankrat'ev, LM; Varshavskiĭ, VA, 1989) |
| "Thirty-five patients with severe chronic congestive heart failure that was refractory to conventional therapy were given high dosages of furosemide (250 to 4000 mg/d) because of significantly reduced renal function (mean endogenous creatinine clearance, 0." | 7.67 | High-dose furosemide in the treatment of refractory congestive heart failure. ( Gerlag, PG; van Meijel, JJ, 1988) |
| "Furosemide occasionally causes azotemia in patients with ascites, independently of induced volume depletion." | 7.67 | Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. ( Daskalopoulos, G; Harley, H; Laffi, G; Morgan, T; Pinzani, M; Reynolds, T; Zipser, RD, 1987) |
| "To define the short-term haemodynamic, hormonal and electrolyte effects of enalapril in chronic heart failure, we administered it to nine patients." | 7.66 | Acute haemodynamic, hormonal and electrolyte effects and short-term clinical response to enalapril in heart failure. ( Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG, 1983) |
| "We studied the effects of furosemide on pulmonary mechanics in 10 infants with bronchopulmonary dysplasia aged 41 +/- 1 (SE) weeks post-conception, gestational age at birth 30 +/- 1 wk, birth weight 1370 +/- 200 gm." | 7.66 | Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. ( Kao, LC; Keens, TG; Platzker, AC; Sargent, CW; Warburton, D, 1983) |
| " Further studies are necessary to evaluate potential pharmacodynamic differences between torasemide formulations and to assess its impact on clinical therapeutics." | 6.80 | Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure. ( Antonijoan, RM; Ballester, MR; Delgadillo, J; Gich, I; Puntes, M; Roig, E; Santos, B, 2015) |
| "Thiamine levels were determined using the erythrocyte transketolase activity." | 6.73 | Influence of spironolactone therapy on thiamine blood levels in patients with heart failure. ( Albanesi Filho, FM; de Albuquerque, DC; Rocha, RM; Silva, GV; Tura, BR, 2008) |
| "The combined prophylactic strategy of sodium bicarbonate plus N-acetylsyteine (NAC) seems to be effective in preventing contrast induced acute kidney injury (CI-AKI) in patients at low-to-medium risk." | 6.25 | Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. ( Briguori, C; Condorelli, G; Ricciardelli, B; Visconti, G, 2011) |
| "Diabetes mellitus has been suggested as a determinant of diuretic resistance." | 5.56 | Diabetic patients need higher furosemide doses: a report on acute and chronic heart failure patients. ( Bettencourt, P; Cunha, FM; Lourenço, P; Marques, P; Pereira, J; Ribeiro, A, 2020) |
| "This is a prospective randomized controlled trial to study the efficacy and safety of Shenfu injection combined with furosemide in the treatment of coronary heart disease and chronic heart failure." | 5.41 | Shenfu injection combined with furosemide in the treatment of chronic heart failure in patients with coronary heart disease: A protocol of randomized controlled trial. ( Gao, Y; Tan, X; Zhu, R, 2021) |
| "Aerosol furosemide may be an option to treat refractory dyspnea, though doses, methods of delivery, and outcomes have been variable." | 5.34 | Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients. ( Banzett, RB; Hallowell, RW; O'Donnell, CR; Schwartzstein, R; Sheridan, A, 2020) |
| " Failed furosemide adherence (defined as < 10% of a dose excreted in 24 h urine where normal average excretion = 50% of an oral dose) during static prescribed dosing was infrequent relative to all days of therapy; yet was equally common across all outcome groups." | 5.32 | Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. ( Brater, DC; Gorski, JC; MacFadyen, RJ; Struthers, AD, 2004) |
| "Torasemide with its more complete and less variable bioavailability offers potential clinical and economic advantages over furosemide in the long-term treatment in patients with CHF." | 5.31 | [Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide?]. ( Falkenstein, P; Follath, F; Gutzwiller, F; Müller, K; Reitberger, U; Spannheimer, A, 2002) |
| "Hyperkalemia was not caused by an adrenal disorder or acidosis and could not be abolished by interventions enhancing K clearance; saline infusions, high doses of furosemide, cortisone, cortisol, long-acting synthetic ACTH and excessive doses of aldosterone." | 5.26 | Hyperkalemia unresponsive to massive doses of aldosterone and renal tubular acidosis in a patient with chronic interstitial nephritis: clinical and experimental studies. ( Radó, JP; Szende, L; Szucs, L, 1976) |
| "The aim of this study was to determine the diuretic effect of acetazolamide in patients with exacerbations of chronic heart failure, in addition to their stable diuretic therapy." | 5.24 | Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study. ( Budaj, A; Imiela, T, 2017) |
| "We have previously reported that a long-acting loop diuretic, azosemide, reduces cardiovascular risks in patients with chronic heart failure (CHF) as compared with a short-acting one, furosemide, in Japanese Multicenter Evaluation of LOng- versus short-acting Diuretics In Congestive heart failure (J-MELODIC)." | 5.24 | Changes in brain natriuretic peptide in chronic heart failure patients treated with long-acting versus short-acting loop diuretics: J-MELODIC subanalysis. ( Akasaka, T; Daimon, T; Fukui, M; Hirano, Y; Hirotani, S; Ito, H; Kawabata, M; Masuyama, T; Nakatani, S; Ohte, N; Tsujino, T; Yamamoto, K, 2017) |
| " The most widely used diuretic, furosemide, has a stormy pharmacokinetics and pharmacodynamics, and is associated with a high risk of mortality and hospitalization for worsening heart failure." | 5.24 | The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial. ( Bakuła, E; Balsam, P; Cacko, A; Filipiak, KJ; Fojt, A; Grabowski, M; Główczyńska, R; Huczek, Z; Kowalik, R; Markulis, M; Opolski, G; Ozierański, K; Peller, M; Sieradzki, B; Tymińska, A, 2017) |
| " Patients in group 1 (125 mg furosemide) had a mean age of 77 ± 17 years, 43% were male, 6 (43%) had heart failure with a preserved ejection fraction (HFpEF), and 64% were in New York Heart Association (NYHA) class IV; the mean age of patients in group 2 (250 mg furosemide) was 80 ± 8." | 5.20 | Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure. ( Balistreri, F; Butler, J; Cuttitta, F; Di Gaudio, F; di Pasquale, P; Greco, M; Indelicato, S; La Rocca, V; Lupo, U; Parrinello, G; Paterna, S; Rizzo, G; Torres, D, 2015) |
| "Spironolactone, not furosemide, improved insulin resistance in CHF patients probably by the inhibition of inflammatory cytokines and MMPs." | 5.19 | Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure. ( Anker, SD; Doehner, W; Hisatome, I; Kato, M; Kinugasa, Y; Ogino, K; Yamamoto, K, 2014) |
| "Furosemide is the diuretic of choice for the treatment of hypertension in chronic kidney disease but the adaptative changes in the distal nephron may decrease its efficacy." | 5.16 | A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2012) |
| "The role of repeated infusions of Levosimendan (LEVO) in patients with chronic advanced heart failure is still unclear." | 5.16 | Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival. ( Branzi, G; Della Rosa, F; Facchini, M; Malfatto, G; Parati, G; Rella, V; Villani, A, 2012) |
| "The aim of this study was to evaluate the effects of both the prolonged-release (PR) formulation of torasemide (torasemide-PR) and furosemide on myocardial fibrosis in hypertensive patients with chronic HF." | 5.15 | Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. ( , 2011) |
| "Loop diuretics, such as torasemide and furosemide, are important agents in the treatment of chronic heart failure." | 5.14 | TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. ( Anguita, M; Castro-Beiras, A; Cobo, E; Coca, A; Conthe, P; de Teresa, E; Díez, J; Fernández, E, 2009) |
| "In patients with CHF, tolvaptan was well tolerated; it reduced body weight and edema and normalized serum sodium in the hyponatremic patients." | 5.10 | Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. ( Czerwiec, F; Gheorghiade, M; Kambayashi, J; Niazi, I; Orlandi, C; Ouyang, J; Zampino, M, 2003) |
| "To demonstrate the long-term efficacy of intranasal furosemide, an inhibitor of the sodium chloride cotransporter channel at the basolateral surface of the respiratory epithelial cell, vs no therapeutic intervention vs intranasal mometasone furoate, a corticosteroid, in preventing relapses of chronic hyperplastic sinusitis with nasal polyposis." | 5.10 | Treatment of recurrent chronic hyperplastic sinusitis with nasal polyposis. ( Bellussi, L; Bernstein, JM; Damiani, V; Passàli, D; Passali, FM; Passàli, GC, 2003) |
| "The hypothesis was that torasemide, due to more predictable pharmacokinetics/pharmacodynamics, induces greater improvements in functional and social limitation than furosemide and reduces the frequency of hospitalisations in primary care patients with chronic heart failure (CHF)." | 5.10 | Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life. ( Gamba, G; Hess, B; Jaquet, F; Müller, K, 2003) |
| "We investigated the effects of a short-acting loop diuretic (furosemide) and a long-acting loop diuretic (azosemide) on heart rate variability, fluid balance, and neurohormonal responses in patients with mild to moderate chronic congestive heart failure." | 5.09 | Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure. ( Doba, N; Imai, Y; Nakayama, T; Sakuma, Y; Shiojima, K; Tomiyama, H; Watanabe, G; Yamamoto, A; Yoshida, H, 1999) |
| "Male patients with mild heart failure were randomly assigned to 9 days of therapy with 20 mg frusemide twice a day, 200 mg candoxatril twice a day, or 400 mg candoxatril twice a day (n = 10 per group) after a 14-day placebo washout phase." | 5.09 | Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. ( Dargie, HJ; Newby, DE; Norrie, J; Northridge, DB; Rooney, E, 1999) |
| "The study aimed to assess the hemodynamic and neuroendocrine effects of candoxatril and frusemide compared with placebo in patients with mild chronic heart failure." | 5.09 | Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. ( Bostrøm, P; Christensen, CC; Parikka, H; Rykke, EO; Toivonen, L; Westheim, AS, 1999) |
| "We sought to determine the effect of aspirin on the venodilator effect of furosemide in patients with chronic heart failure (CHF) BACKGROUND: Furosemide has an acute venodilator effect preceding its diuretic action, which is blocked by nonsteroidal anti-inflammatory, drugs." | 5.09 | Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. ( Davie, AP; Jhund, PS; McMurray, JJ, 2001) |
| "We studied the synergism between high-dose furosemide and hydrochlorothiazide in patients with severe congestive heart failure and impaired renal function showing diuretic resistance to a daily dose of furosemide of at least 250 mg." | 5.08 | Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. ( Dormans, TP; Gerlag, PG, 1996) |
| "This study was designed to investigate whether a subclinical accumulation of fluid in the lung interstitium associated with moderate congestive heart failure interferes with the patient's functional capacity, and whether furosemide treatment can promote reabsorption of the excessive fluid." | 5.07 | Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. ( Agostoni, P; Guazzi, MD; Lauri, G; Marenzi, G; Perego, G; Schianni, M; Sganzerla, P, 1994) |
| "This study examined the effects of conventional doses of oral captopril on the renal responses to oral furosemide in ambulant patients with stable chronic heart failure." | 5.07 | Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. ( Bridges, AB; Fraser, CG; McLay, JS; McMurray, JJ; Struthers, AD, 1993) |
| "To analyze the physical performance of the patients with congestive heart failure (CHF), grades I and II of the New York Heart Association (NYHA), submitted to ergometric test: 1) under conventional treatment with digitalis and diuretic; 2) with an angiotensin converting enzyme inhibitor, captopril, associate with conventional treatment; 3) using captopril associated with digitalis or diuretic." | 5.07 | [Captopril in the treatment of patients with congestive heart failure. Its bicycle ergometry evaluation]. ( Benchimol, C; Ferreira Filho, SR; Hatab, SA; Nascimento, LO; Saragoça, MA, 1992) |
| "To test the hypothesis that alternate-day administration of furosemide will result in a sustained improvement in pulmonary function without causing alterations in electrolyte or mineral homeostasis, we conducted a randomized, double-blind, placebo-controlled study of 11 hospitalized, oxygen-dependent, spontaneously breathing infants with chronic bronchopulmonary dysplasia." | 5.06 | Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. ( Engelhardt, B; Hazinski, TA; Parker, RA; Rush, MG, 1990) |
| "18 patients with II NYHA class chronic congestive heart failure (CCHF) had been given nifedipine (Cordipin) 54." | 5.06 | [Evaluation of the effect of nifedipine in patients with chronic congestive heart failure]. ( Bechler-Lisińska, J; Broks-Bratkowska, B; Cholewa, M; Dryjański, T; Gawor, Z; Górski, L; Markiewicz, K, 1989) |
| "Captopril alone as therapy for mild heart failure was compared with a combination of frusemide and amiloride in a double-blind randomised crossover trial in 14 patients who had previously been treated with diuretics." | 5.06 | Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. ( Bayliss, J; Parameshwar, J; Poole-Wilson, PA; Richardson, A; Scriven, AJ; Sutton, GC, 1987) |
| "Renal function and excretion of water, salt, and the prostacyclin hydration product (6-keto-PGF1 alpha) were evaluated in 10 furosemide-treated patients with well-controlled congestive heart failure." | 5.06 | Renal function and tubular transport effects of sulindac and naproxen in chronic heart failure. ( Beermann, B; Eriksson, LO; Kallner, M, 1987) |
| "The diuretic effects of torasemide and of furosemide were compared in a double blind cross-over study in 13 patients with stable chronic heart failure." | 5.06 | Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. ( Delarge, J; Luyckx, AS; Scheen, AJ; Vancrombreucq, JC, 1986) |
| " The incidence of severe hypertension was significantly lower when nifedipine (odds ratio, 0." | 5.05 | Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. ( Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020) |
| "Approximately one-third of patients with acute decompensated heart failure (ADHF) treated with an intravenous (iv) loop diuretic at a relatively high dose (>80 mg/day of furosemide, or an equivalent dose of another loop diuretic), exhibit worsening renal function (WRF) after a single course of iv infusions or iv bolus injections maintained for several days." | 3.83 | Poor concordance between different definitions of worsening renal function in patients with acute exacerbation of chronic heart failure: a retrospective study. ( Baldi, C; De Vecchis, R; Di Biase, G, 2016) |
| "We give account of a patient, who works in health care, with bulimia nervosa (BN) and a long term abuse of Furosemide." | 3.81 | [Diuretic-Abuse in Chronic Bulimia Nervosa--Case Report and Clinical Management]. ( Bröckel-Ristevski, N; Cuntz, U; Fumi, M; Greetfeld, M; Voderholzer, U, 2015) |
| "To ascertain whether increasing doses of orally administered furosemide are associated with impaired survival in outpatients with chronic heart failure (CHF) and left ventricular (LV) systolic dysfunction." | 3.79 | Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. ( Cicoira, M; Dini, FL; Genta, FT; Ghio, S; Klersy, C; Rossi, A; Scelsi, L; Simioniuc, A; Tavazzi, L; Temporelli, PL, 2013) |
| "In an experimental heart failure model, we tested the hypothesis that furosemide causes excess mortality." | 3.78 | Furosemide induces mortality in a rat model of chronic heart failure. ( Anker, SD; Bauersachs, J; Bockmeyer, B; Doehner, W; Hocher, B; Rokutan, H; Springer, J; Strassburg, S; Suckow, C; von Haehling, S; von Websky, K; Waller, C, 2012) |
| "The objective of the TOrasemide In Congestive Heart Failure (TORIC) Study was to investigate the safety, tolerability and efficacy of torasemide in CHF patients compared to furosemide or other diuretics in an open-label, non-randomised, post-marketing surveillance trial." | 3.71 | Torasemide in chronic heart failure: results of the TORIC study. ( Cosín, J; Díez, J, 2002) |
| "The effect of enalapril, digoxin and frusemide combination on clinical, biochemical and anthropometric indices were determined in eight cachectic Nigerians with chronic congestive heart failure [body mass index (BMI) 20." | 3.71 | The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. ( Adigun, AQ; Ajayi, AA, 2001) |
| "We evaluated the comparative effects of furosemide, a short-acting loop diuretic, and azosemide, a long-acting loop diuretic, on neurohumoral factors and quality of life (QOL) in patients with congestive heart failure (CHF)." | 3.71 | Comparison of neurohumoral effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure. ( Kinoshita, M; Maeda, K; Tsutamoto, T; Tsutsui, T, 2001) |
| "We studied the effects of inhaled furosemide (40 mg) on bronchial responsiveness to acetylcholine (ACh) in patients with chronic congestive heart failure who had been premedicated with indomethacin (75 mg/day) for five days." | 3.69 | [Effects of inhaled furosemide after indomethacin premedication on bronchial hyperresponsiveness in patients with chronic congestive heart failure]. ( Ishizaki, T; Kanamori, K; Mifune, J; Miyabo, S; Nakai, T; Saitoh, Y; Sakai, T; Sasaki, F, 1994) |
| "The hypothesis that endogenous PGE2 mediates defective thick ascending limb (TAL) Cl reabsorption (percent delivered load: FRCl%) in rats with vitamin D-induced chronic hypercalcemia (HC) was tested by measuring FRCl% in loop segments microperfused in vivo in HC and control rats treated acutely with indomethacin (Indo) or its vehicle, and obtaining the corresponding outer medullary [PGE2]." | 3.68 | Endogenous prostaglandin E2 mediates inhibition of rat thick ascending limb Cl reabsorption in chronic hypercalcemia. ( Borzecki, JS; McKay, AJ; Peterson, LN, 1993) |
| "We studied the effects of inhaled and intravenous furosemide (40 mg) on bronchial responsiveness to acetylcholine (ACh) in patients with chronic congestive heart failure." | 3.68 | [Effects of inhaled and intravenous furosemide on bronchial hyperresponsiveness in patients with chronic congestive heart failure]. ( Fujimura, M; Hifumi, S; Ishizaki, T; Mifune, J; Miyabo, S; Nakai, T; Sakai, T; Sasaki, F; Takahashi, H, 1992) |
| "Intravenous sodium bicarbonate (NaHCO3) infusion test was performed in 26 patients with chronic glomerulonephritis (CGN) and 16 with distal renal tubular acidosis (dRTA) in order to evaluate urinary acidifying capacity in chronic renal diseases." | 3.68 | [Glomerular function and urine acidification in chronic renal diseases]. ( Mizukami, K, 1990) |
| "1 yrs) with III or IV NYHa class congestive heart failure after 2-week therapy with digoxin (D) and furosemide (F) underwent two-dimensional echocardiographic examination to assess left ventricular function." | 3.68 | [Changes in left-ventricular function in chronic congestive heart failure treated with digoxin, furosemide and vasodilators]. ( Cholewa, M; Dryjański, T; Gawor, Z; Markiewicz, K, 1990) |
| " Rats were divided into four groups as follows: normokalemic control (group I, n = 10), acute hypokalemia with furosemide (group II, n = 16), acute hypokalemia with hyperventilation (group III, n = 18), and chronic hypokalemia induced by a low potassium (K+) diet (group IV, n = 22)." | 3.67 | Hypokalemia in rats produces resistance to dysrhythmias under halothane anesthesia. ( Farina, JP; Kwon, NJ; Stolte, AL, 1989) |
| "The data on protein excretion with urine under the effect of furosemide were compared clinically and morphologically with the morphological signs of tubulostromal lesions in the kidneys in 19 patients suffering from amyloid nephropathy and in 33 patients with chronic glomerulonephritis." | 3.67 | [Effect of furosemide on proteinuria in patients suffering from amyloidosis and chronic nephritis with various tubulostromal lesions of the kidneys]. ( Pankrat'ev, LM; Varshavskiĭ, VA, 1989) |
| "Thirty-five patients with severe chronic congestive heart failure that was refractory to conventional therapy were given high dosages of furosemide (250 to 4000 mg/d) because of significantly reduced renal function (mean endogenous creatinine clearance, 0." | 3.67 | High-dose furosemide in the treatment of refractory congestive heart failure. ( Gerlag, PG; van Meijel, JJ, 1988) |
| "Furosemide occasionally causes azotemia in patients with ascites, independently of induced volume depletion." | 3.67 | Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. ( Daskalopoulos, G; Harley, H; Laffi, G; Morgan, T; Pinzani, M; Reynolds, T; Zipser, RD, 1987) |
| "To define the short-term haemodynamic, hormonal and electrolyte effects of enalapril in chronic heart failure, we administered it to nine patients." | 3.66 | Acute haemodynamic, hormonal and electrolyte effects and short-term clinical response to enalapril in heart failure. ( Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG, 1983) |
| "We studied the effects of furosemide on pulmonary mechanics in 10 infants with bronchopulmonary dysplasia aged 41 +/- 1 (SE) weeks post-conception, gestational age at birth 30 +/- 1 wk, birth weight 1370 +/- 200 gm." | 3.66 | Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. ( Kao, LC; Keens, TG; Platzker, AC; Sargent, CW; Warburton, D, 1983) |
| "To study the physiological tolerance to asphyxia and hypokalemia during anesthesia, the cardiovascular responses to clamping of the endotracheal tube during mechanical ventilation were evaluated in ten anesthetized mongrel dogs before and after they had been made hypokalemic by administration of furosemide, 10 mg X kg-1 X day-1 for 3-4 weeks." | 3.66 | Cardiovascular responses to asphyxial challenge in chronically hypokalemic dogs. ( Port, JD; Steffins, J; Wong, KC, 1983) |
| "CLOROTIC is the first large-scale trial to evaluate whether the addition of a thiazide diuretic (hydrochlorothiazide) to a loop diuretic (furosemide) is a safe and effective strategy for improving congestive symptoms resulting from HF." | 2.82 | Rationale and Design of the "Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) Trial:" A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effect of Combin ( Casado, J; Formiga, F; Freitas Ramírez, A; Manzano, L; Morales-Rull, JL; Trullàs, JC, 2016) |
| " Further studies are necessary to evaluate potential pharmacodynamic differences between torasemide formulations and to assess its impact on clinical therapeutics." | 2.80 | Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure. ( Antonijoan, RM; Ballester, MR; Delgadillo, J; Gich, I; Puntes, M; Roig, E; Santos, B, 2015) |
| "Thiamine levels were determined using the erythrocyte transketolase activity." | 2.73 | Influence of spironolactone therapy on thiamine blood levels in patients with heart failure. ( Albanesi Filho, FM; de Albuquerque, DC; Rocha, RM; Silva, GV; Tura, BR, 2008) |
| " On long term evaluation in an open design (Phase II), wherein Phase I participants continued Terminalia Arjuna in fixed dosage (500 mg 8-hourly) in addition to flexible diuretic, vasodilator and digitalis dosage for 20-28 months (mean 24 months) on outpatient basis, patients showed continued improvement in symptoms, signs, effort tolerance and NYHA Class, with improvement in quality of life." | 2.68 | Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. ( Bharani, A; Bhargava, KD; Ganguly, A, 1995) |
| " The absolute bioavailability of frusemide during hypoxaemia (0." | 2.68 | The effect of hypoxaemia on drug disposition in chronic respiratory failure. ( Hayball, PJ; Henderson, G; Latimer, K; May, F; Rowett, D; Ruffin, RE; Sansom, LN, 1996) |
| "All furosemide-treated patients had high levels of urinary calcium (12." | 2.67 | Furosemide effect on mineral status of parenterally nourished premature neonates with chronic lung disease. ( Vileisis, RA, 1990) |
| "Heart failure is one of the most common disorders after malignant diseases." | 2.66 | [The Role of Pharmacists in Home Medical Care of Patients with Heart Failure]. ( Gyoda, Y; Kawauchi, J; Oikawa, Y; Sakuma, E; Watanabe, J, 2020) |
| " Frusemide in a dosage of 0." | 2.66 | A comparison of intravenous elantan and frusemide in patients with chronic cardiac failure. ( Hutton, I; Martin, W; McGhie, AI; Tweddel, AC, 1987) |
| "Chronic breathlessness is a troublesome symptom experienced by people with advanced malignant and nonmalignant disease." | 2.61 | Updates in opioid and nonopioid treatment for chronic breathlessness. ( Abdallah, SJ; Jensen, D; Lewthwaite, H, 2019) |
| " It is a high-ceiling diuretic that has a longer half-life, longer duration of action and higher bioavailability compared to furosemide." | 2.46 | [Update: prolonged-release torasemide]. ( Acuña, C, 2010) |
| "Hyponatremia is the most common electrolyte abnormality." | 2.44 | [Etiology, diagnostics and therapy of hyponatremias]. ( Laczi, F, 2008) |
| "Furosemide was the only diuretic used in the eight studies included in this review." | 2.43 | Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. ( Brion, LP; Primhak, RA; Yong, W, 2006) |
| "Furosemide was the only diuretic used in the eight studies included in this review." | 2.41 | Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. ( Brion, LP; Primhak, RA; Yong, W, 2000) |
| "Treatment with prednisone, furosemide and theophylline was started, which led to a gradual improvement in 2 weeks and a persistent remission after 9 months." | 2.41 | Chronic systemic capillary leak syndrome. Report of a case and review of the literature. ( Airaghi, L; Miadonna, A; Montori, D; Santambrogio, L; Tedeschi, A, 2000) |
| "Furosemide was the only diuretic used in the eight studies included in this review." | 2.41 | Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. ( Brion, LP; Primhak, RA; Yong, W, 2001) |
| "Diabetes mellitus has been suggested as a determinant of diuretic resistance." | 1.56 | Diabetic patients need higher furosemide doses: a report on acute and chronic heart failure patients. ( Bettencourt, P; Cunha, FM; Lourenço, P; Marques, P; Pereira, J; Ribeiro, A, 2020) |
| "Nitrates were given most often in pulmonary oedema and hypertensive AHF." | 1.39 | Management of acute heart failure and the effect of systolic blood pressure on the use of intravenous therapies. ( Harjola, VP; Lassus, J; Nieminen, MS; Siirilä-Waris, K; Tarvasmäki, T; Tolonen, J, 2013) |
| " Actually, a significant association with ARD was not present in any CHF patient with dilated left ventricle treated with high dosage of iv FUR, whereas a highly significant association with ARD was observed in HFNEF patients (OR: 72 95% CI: 6." | 1.37 | In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function. ( Ariano, C; Cantatrione, S; Ciccarelli, A; Cioppa, C; De Vecchis, R; Giasi, A; Pucciarelli, A, 2011) |
| "Heart failure is often treated with ACE inhibitors and diuretics although diuretic treatment could activate the renin-angiotensin system (RAS)." | 1.32 | Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats. ( Böhm, M; Itter, G; Jockenhövel, F; Kouchi, I; Linz, W; Seeland, U; Zolk, O, 2003) |
| " Failed furosemide adherence (defined as < 10% of a dose excreted in 24 h urine where normal average excretion = 50% of an oral dose) during static prescribed dosing was infrequent relative to all days of therapy; yet was equally common across all outcome groups." | 1.32 | Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. ( Brater, DC; Gorski, JC; MacFadyen, RJ; Struthers, AD, 2004) |
| "Torasemide with its more complete and less variable bioavailability offers potential clinical and economic advantages over furosemide in the long-term treatment in patients with CHF." | 1.31 | [Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide?]. ( Falkenstein, P; Follath, F; Gutzwiller, F; Müller, K; Reitberger, U; Spannheimer, A, 2002) |
| "They examined 25 patients with bronchial asthma and chronic obstructive bronchitis (mean age 49 years)." | 1.31 | [The furosemide test in diagnosis of the cause of bronchial obstruction]. ( Kosinarova, V; Redhammer, R; Tamasova, M; Urban, S, 2001) |
| "Normocapnic and chronic hypercapnic COPD patients have the same ventilatory and cerebrovascular carbon dioxide responsiveness irrespective of induced metabolic state." | 1.31 | Effects of acetazolamide and furosemide on ventilation and cerebral blood volume in normocapnic and hypercapnic patients with COPD. ( Colier, WN; Folgering, H; Oeseburg, B; van de Ven, MJ; van der Sluijs, MC; Vis, P, 2002) |
| "She was suspected of having Bartter's syndrome because of hypokalemia, metabolic alkalosis, hyperreninemia, hyperaldosteronism and normotension." | 1.30 | [A case of Bartter's syndrome with chronic renal failure due to chronic interstitial nephritis]. ( Dohi, K; Fujii, Y; Fujimoto, T; Kanauchi, M; Maekawa, K; Murata, K; Shiiki, H; Takayanagi, T, 1998) |
| "Renal calculi were seen in four patients, sonographically demonstrated as echogenic foci in the dependent portion of the collecting system, usually accompanied by acoustic shadowing." | 1.27 | Ultrasound diagnosis of renal calcification in infants on chronic furosemide therapy. ( Adelman, RD; Goetzman, BW; McGahan, JP; Myracle, MR, 1986) |
| "The bioavailability and diuretic effect of furosemide 40 mg administered orally for at least 6 months have been compared in patients with chronic respiratory failure and in healthy controls." | 1.27 | Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure. ( Haga, T; Kawatsu, Y; Machida, K; Maruyama, Y; Ogata, H, 1985) |
| " Similarities in their clinical courses included low birthweights, low calcium intakes, uncertain vitamin D intakes, and chronic administration of frusemide and sodium bicarbonate--all potential aetiological factors in the development of bone undermineralisation." | 1.26 | Nutritional rickets in 2 very low birthweight infants with chronic lung disease. ( Brown, DR; Chudley, AE; Holzman, IR; Oh, KS, 1980) |
| "Hyperkalemia was not caused by an adrenal disorder or acidosis and could not be abolished by interventions enhancing K clearance; saline infusions, high doses of furosemide, cortisone, cortisol, long-acting synthetic ACTH and excessive doses of aldosterone." | 1.26 | Hyperkalemia unresponsive to massive doses of aldosterone and renal tubular acidosis in a patient with chronic interstitial nephritis: clinical and experimental studies. ( Radó, JP; Szende, L; Szucs, L, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 77 (38.50) | 18.7374 |
| 1990's | 41 (20.50) | 18.2507 |
| 2000's | 36 (18.00) | 29.6817 |
| 2010's | 37 (18.50) | 24.3611 |
| 2020's | 9 (4.50) | 2.80 |
| Authors | Studies |
|---|---|
| Frea, S | 2 |
| Pidello, S | 2 |
| Bergerone, S | 2 |
| D'Ascenzo, F | 2 |
| Cunha, FM | 1 |
| Pereira, J | 1 |
| Marques, P | 1 |
| Ribeiro, A | 1 |
| Bettencourt, P | 4 |
| Lourenço, P | 3 |
| Hallowell, RW | 1 |
| Schwartzstein, R | 1 |
| O'Donnell, CR | 1 |
| Sheridan, A | 1 |
| Banzett, RB | 1 |
| Segar, JL | 2 |
| Bellos, I | 1 |
| Pergialiotis, V | 1 |
| Papapanagiotou, A | 1 |
| Loutradis, D | 1 |
| Daskalakis, G | 1 |
| Sakuma, E | 1 |
| Kawauchi, J | 1 |
| Gyoda, Y | 1 |
| Oikawa, Y | 1 |
| Watanabe, J | 1 |
| Simonavičius, J | 1 |
| Maeder, MT | 1 |
| Eurlings, CGMJ | 1 |
| Aizpurua, AB | 1 |
| Čelutkienė, J | 1 |
| Barysienė, J | 1 |
| Toggweiler, S | 1 |
| Kaufmann, BA | 1 |
| Brunner-La Rocca, HP | 2 |
| Gao, Y | 2 |
| Zhu, R | 1 |
| Tan, X | 1 |
| Laszczyńska, O | 1 |
| Severo, M | 1 |
| Friões, F | 1 |
| Silva, S | 1 |
| Lunet, N | 1 |
| Azevedo, A | 2 |
| Imiela, T | 1 |
| Budaj, A | 1 |
| Linssen, GC | 1 |
| Smeele, FJ | 1 |
| van Drimmelen, AA | 1 |
| Schaafsma, HJ | 1 |
| Westendorp, PH | 1 |
| Rademaker, PC | 1 |
| van de Kamp, HJ | 1 |
| Hoes, AW | 1 |
| Brugts, JJ | 1 |
| Nam, YH | 1 |
| Bilker, WB | 1 |
| Leonard, CE | 1 |
| Bell, ML | 1 |
| Hennessy, S | 1 |
| Volpe, A | 1 |
| Canavosio, FG | 1 |
| Galluzzo, A | 1 |
| Bovolo, V | 1 |
| Camarda, A | 1 |
| Golzio, PG | 1 |
| Rinaldi, M | 1 |
| Gaita, F | 1 |
| Abdallah, SJ | 1 |
| Jensen, D | 1 |
| Lewthwaite, H | 1 |
| Dini, FL | 1 |
| Ghio, S | 1 |
| Klersy, C | 1 |
| Rossi, A | 1 |
| Simioniuc, A | 1 |
| Scelsi, L | 1 |
| Genta, FT | 1 |
| Cicoira, M | 1 |
| Tavazzi, L | 1 |
| Temporelli, PL | 1 |
| Ferreira, JP | 1 |
| Santos, M | 1 |
| Almeida, S | 1 |
| Marques, I | 1 |
| Carvalho, H | 1 |
| Tarvasmäki, T | 1 |
| Harjola, VP | 1 |
| Tolonen, J | 1 |
| Siirilä-Waris, K | 1 |
| Nieminen, MS | 1 |
| Lassus, J | 1 |
| Ogino, K | 1 |
| Kinugasa, Y | 1 |
| Kato, M | 1 |
| Yamamoto, K | 3 |
| Hisatome, I | 1 |
| Anker, SD | 3 |
| Doehner, W | 2 |
| Wu, ZL | 1 |
| Ren, H | 1 |
| Lai, WY | 1 |
| Lin, S | 1 |
| Jiang, RY | 1 |
| Ye, TC | 1 |
| Shen, QB | 1 |
| Zeng, QC | 1 |
| Xu, DL | 1 |
| De Vecchis, R | 2 |
| Baldi, C | 1 |
| Di Biase, G | 1 |
| Greetfeld, M | 1 |
| Bröckel-Ristevski, N | 1 |
| Fumi, M | 1 |
| Cuntz, U | 1 |
| Voderholzer, U | 1 |
| Ballester, MR | 1 |
| Roig, E | 1 |
| Gich, I | 1 |
| Puntes, M | 1 |
| Delgadillo, J | 1 |
| Santos, B | 1 |
| Antonijoan, RM | 1 |
| Paterna, S | 1 |
| Di Gaudio, F | 1 |
| La Rocca, V | 1 |
| Balistreri, F | 1 |
| Greco, M | 1 |
| Torres, D | 1 |
| Lupo, U | 1 |
| Rizzo, G | 1 |
| di Pasquale, P | 1 |
| Indelicato, S | 1 |
| Cuttitta, F | 1 |
| Butler, J | 1 |
| Parrinello, G | 1 |
| Trullàs, JC | 1 |
| Morales-Rull, JL | 1 |
| Casado, J | 1 |
| Freitas Ramírez, A | 1 |
| Manzano, L | 1 |
| Formiga, F | 1 |
| Damman, K | 1 |
| Kjekshus, J | 1 |
| Wikstrand, J | 1 |
| Cleland, JG | 3 |
| Komajda, M | 1 |
| Wedel, H | 1 |
| Waagstein, F | 1 |
| McMurray, JJ | 3 |
| Voors, AA | 1 |
| Dickstein, K | 1 |
| Filippatos, G | 1 |
| van der Harst, P | 1 |
| Hillege, HL | 1 |
| Lang, CC | 1 |
| Ter Maaten, JM | 1 |
| Ng, L | 1 |
| Ponikowski, P | 1 |
| Samani, NJ | 1 |
| van Veldhuisen, DJ | 1 |
| Zannad, F | 1 |
| Zwinderman, AH | 1 |
| Metra, M | 1 |
| Filippatos, TD | 1 |
| Liamis, G | 1 |
| Elisaf, MS | 1 |
| Fukui, M | 1 |
| Tsujino, T | 2 |
| Hirotani, S | 1 |
| Ito, H | 2 |
| Akasaka, T | 2 |
| Hirano, Y | 2 |
| Ohte, N | 2 |
| Daimon, T | 2 |
| Nakatani, S | 2 |
| Kawabata, M | 1 |
| Masuyama, T | 2 |
| Balsam, P | 1 |
| Ozierański, K | 1 |
| Tymińska, A | 1 |
| Główczyńska, R | 1 |
| Peller, M | 1 |
| Fojt, A | 1 |
| Cacko, A | 1 |
| Sieradzki, B | 1 |
| Bakuła, E | 1 |
| Markulis, M | 1 |
| Kowalik, R | 1 |
| Huczek, Z | 1 |
| Filipiak, KJ | 1 |
| Opolski, G | 1 |
| Grabowski, M | 1 |
| Rocha, RM | 1 |
| Silva, GV | 1 |
| de Albuquerque, DC | 1 |
| Tura, BR | 1 |
| Albanesi Filho, FM | 1 |
| Laczi, F | 1 |
| Díez, J | 2 |
| Coca, A | 1 |
| de Teresa, E | 1 |
| Anguita, M | 1 |
| Castro-Beiras, A | 1 |
| Conthe, P | 1 |
| Cobo, E | 1 |
| Fernández, E | 1 |
| Grundtvig, M | 1 |
| Westheim, A | 1 |
| Hole, T | 1 |
| Flønaes, B | 1 |
| Gullestad, L | 1 |
| Rognant, N | 1 |
| Guebre-Egziabher, F | 1 |
| Bacchetta, J | 1 |
| Janier, M | 1 |
| Hiba, B | 1 |
| Langlois, JB | 1 |
| Gadet, R | 1 |
| Laville, M | 1 |
| Juillard, L | 1 |
| Acuña, C | 1 |
| Ciccarelli, A | 1 |
| Ariano, C | 1 |
| Cioppa, C | 1 |
| Giasi, A | 1 |
| Pucciarelli, A | 1 |
| Cantatrione, S | 1 |
| Martins, J | 1 |
| Araújo, JP | 1 |
| Mascarenhas, J | 1 |
| Lopes, R | 1 |
| Zacharias, H | 1 |
| Raw, J | 1 |
| Nunn, A | 1 |
| Parsons, S | 1 |
| Johnson, M | 1 |
| Rokutan, H | 1 |
| Suckow, C | 1 |
| von Haehling, S | 1 |
| Strassburg, S | 1 |
| Bockmeyer, B | 1 |
| Waller, C | 1 |
| Bauersachs, J | 1 |
| von Websky, K | 1 |
| Hocher, B | 1 |
| Springer, J | 1 |
| Briguori, C | 1 |
| Visconti, G | 1 |
| Ricciardelli, B | 1 |
| Condorelli, G | 1 |
| Hisatake, S | 1 |
| Nanjo, S | 1 |
| Fujimoto, S | 1 |
| Yamashina, S | 1 |
| Yuzawa, H | 1 |
| Namiki, A | 1 |
| Nakano, H | 1 |
| Yamazaki, J | 1 |
| Takenaka, T | 1 |
| Uchida, K | 1 |
| Kojima, E | 1 |
| Gen, S | 1 |
| Nodaira, Y | 1 |
| Hoshi, H | 1 |
| Kato, N | 1 |
| Takane, H | 1 |
| Ohno, Y | 1 |
| Suzuki, H | 1 |
| Celik, T | 1 |
| Yuksel, UC | 1 |
| Stewart, A | 1 |
| Brion, LP | 7 |
| Dussol, B | 1 |
| Moussi-Frances, J | 1 |
| Morange, S | 1 |
| Somma-Delpero, C | 1 |
| Mundler, O | 1 |
| Berland, Y | 1 |
| Miyata, M | 1 |
| Sasaki, T | 2 |
| Ikeda, Y | 1 |
| Shinsato, T | 1 |
| Kubozono, T | 1 |
| Furusho, Y | 1 |
| Kusumoto, A | 1 |
| Hamasaki, S | 1 |
| Tei, C | 1 |
| Origasa, H | 1 |
| Malfatto, G | 1 |
| Della Rosa, F | 1 |
| Villani, A | 1 |
| Rella, V | 1 |
| Branzi, G | 1 |
| Facchini, M | 1 |
| Parati, G | 1 |
| Cosín, J | 1 |
| Spannheimer, A | 1 |
| Müller, K | 2 |
| Falkenstein, P | 1 |
| Reitberger, U | 1 |
| Gutzwiller, F | 1 |
| Follath, F | 1 |
| Jourdain, P | 1 |
| Funck, F | 1 |
| Bellorini, M | 1 |
| Guillard, N | 1 |
| Loiret, J | 1 |
| Thebault, B | 1 |
| Desnos, M | 1 |
| Duboc, D | 1 |
| Gheorghiade, M | 1 |
| Niazi, I | 1 |
| Ouyang, J | 1 |
| Czerwiec, F | 1 |
| Kambayashi, J | 1 |
| Zampino, M | 1 |
| Orlandi, C | 1 |
| Seeland, U | 1 |
| Kouchi, I | 1 |
| Zolk, O | 1 |
| Jockenhövel, F | 1 |
| Itter, G | 1 |
| Linz, W | 1 |
| Böhm, M | 1 |
| Passàli, D | 1 |
| Bernstein, JM | 1 |
| Passali, FM | 1 |
| Damiani, V | 1 |
| Passàli, GC | 1 |
| Bellussi, L | 1 |
| Gamba, G | 1 |
| Jaquet, F | 1 |
| Hess, B | 1 |
| MacFadyen, RJ | 1 |
| Gorski, JC | 1 |
| Brater, DC | 1 |
| Struthers, AD | 3 |
| Tokumoto, T | 1 |
| Tanabe, K | 1 |
| Toma, H | 1 |
| Akiba, T | 1 |
| Minutolo, R | 2 |
| De Nicola, L | 2 |
| Zamboli, P | 2 |
| Chiodini, P | 1 |
| Signoriello, G | 1 |
| Toderico, C | 1 |
| Arfè, G | 1 |
| Boschi, G | 1 |
| Brancati, C | 1 |
| Iaccarino, P | 1 |
| Conte, G | 2 |
| Ennezat, PV | 1 |
| Ennezat, CA | 1 |
| Vijayaraman, P | 1 |
| Lachmann, J | 1 |
| Asseman, P | 1 |
| Cohen-Solal, A | 1 |
| Sonnenblick, EH | 1 |
| LeJemtel, TH | 1 |
| Starklint, J | 1 |
| Bech, JN | 1 |
| Nyvad, O | 1 |
| Jensen, P | 1 |
| Pedersen, EB | 1 |
| Primhak, RA | 6 |
| Yong, W | 3 |
| Bertino, V | 1 |
| Catapano, F | 1 |
| Sohn, IS | 1 |
| Jin, ES | 1 |
| Cho, JM | 1 |
| Kim, CJ | 1 |
| Bae, JH | 1 |
| Moon, JY | 1 |
| Lee, SH | 1 |
| Kim, MJ | 1 |
| Arai, A | 1 |
| Yan, W | 1 |
| Wakabayashi, S | 1 |
| Hayashi, S | 1 |
| Inazawa, J | 1 |
| Miura, O | 1 |
| Fitzpatrick, D | 1 |
| Nicholls, MG | 2 |
| Ikram, H | 2 |
| Espiner, EA | 2 |
| Natochin, IuV | 1 |
| Govyrin, VA | 1 |
| Papaian, AV | 1 |
| Zhukovskaia, EA | 1 |
| Lavrova, EA | 1 |
| Sommers, SC | 1 |
| Higgins, TE | 1 |
| Kimelblatt, BJ | 1 |
| Kao, LC | 1 |
| Warburton, D | 1 |
| Sargent, CW | 1 |
| Platzker, AC | 1 |
| Keens, TG | 1 |
| Wong, KC | 1 |
| Port, JD | 1 |
| Steffins, J | 1 |
| Jablonski, K | 1 |
| Tronnier, H | 1 |
| Breathnach, SM | 1 |
| Dutt, MK | 1 |
| Black, MM | 1 |
| Decaux, G | 1 |
| Waterlot, Y | 1 |
| Genette, F | 1 |
| Hallemans, R | 1 |
| Demanet, JC | 1 |
| Grzegorzewska, A | 1 |
| Baczyk, K | 1 |
| Berkowitz, RL | 1 |
| Lis, W | 1 |
| Crespi, H | 1 |
| Armando, I | 1 |
| Tumilasci, O | 1 |
| Levin, G | 1 |
| Massimo, J | 1 |
| Barontini, M | 1 |
| Perec, C | 1 |
| Mukharliamov, NM | 2 |
| Ataullakhanova, DM | 1 |
| Sazonova, LN | 2 |
| Chudley, AE | 1 |
| Brown, DR | 1 |
| Holzman, IR | 1 |
| Oh, KS | 1 |
| Warrier, ER | 1 |
| Balakrishnan, KG | 1 |
| Sankaran, K | 1 |
| Gupta, GD | 1 |
| García Puig, J | 1 |
| Mateos Anton, F | 1 |
| Anciones, B | 1 |
| Grande, C | 1 |
| Gilaquado, A | 1 |
| Arnalich, F | 1 |
| Barbado, J | 1 |
| Vázquez, JJ | 1 |
| Gisbert, P | 1 |
| Martin, P | 1 |
| Casares, M | 1 |
| Riñón, M | 1 |
| Ortíz Vázquez, J | 1 |
| Montero García, A | 1 |
| Pytel', IuA | 1 |
| Likhoded, VG | 1 |
| Shapiro, SB | 1 |
| Drobyshevskaia, EI | 1 |
| Tsomyk, VG | 1 |
| Lawson-Matthew, PJ | 1 |
| McLean, KA | 1 |
| Dent, M | 1 |
| Austin, CA | 1 |
| Channer, KS | 1 |
| Siddiqui, MA | 1 |
| Zaman, MN | 1 |
| Bharani, A | 1 |
| Ganguly, A | 1 |
| Bhargava, KD | 1 |
| Miller, M | 1 |
| Solomon, R | 1 |
| Werner, C | 1 |
| Mann, D | 1 |
| D'Elia, J | 1 |
| Silva, P | 1 |
| Chin, T | 1 |
| Franchi, L | 1 |
| Nussbaum, E | 1 |
| Shirley, DG | 1 |
| Skinner, J | 1 |
| Saitoh, Y | 1 |
| Sasaki, F | 2 |
| Sakai, T | 2 |
| Ishizaki, T | 2 |
| Nakai, T | 2 |
| Miyabo, S | 2 |
| Kanamori, K | 1 |
| Mifune, J | 2 |
| Agostoni, P | 1 |
| Marenzi, G | 1 |
| Lauri, G | 1 |
| Perego, G | 1 |
| Schianni, M | 1 |
| Sganzerla, P | 1 |
| Guazzi, MD | 1 |
| De Bock, V | 1 |
| Mets, T | 1 |
| Romagnoli, M | 1 |
| Derde, MP | 1 |
| McLay, JS | 1 |
| Bridges, AB | 1 |
| Fraser, CG | 1 |
| Peterson, LN | 1 |
| McKay, AJ | 1 |
| Borzecki, JS | 1 |
| Dormans, TP | 2 |
| Huige, RM | 1 |
| Gerlag, PG | 3 |
| Rowett, D | 1 |
| Latimer, K | 1 |
| Sansom, LN | 1 |
| Ruffin, RE | 1 |
| May, F | 1 |
| Henderson, G | 1 |
| Hayball, PJ | 1 |
| Chemtob, S | 1 |
| Bell, EF | 1 |
| Ohki, Y | 1 |
| Nako, Y | 1 |
| Koizumi, T | 1 |
| Morikawa, A | 1 |
| Lauriat, SM | 1 |
| Berl, T | 1 |
| Miyamoto, T | 1 |
| Kubo, T | 1 |
| Matsuo, H | 2 |
| Miyatake, K | 1 |
| Lévy, P | 1 |
| Perniceni, T | 1 |
| Gayet, B | 1 |
| Koller-Strametz, J | 1 |
| Pacher, R | 1 |
| Frey, B | 1 |
| Kos, T | 1 |
| Woloszczuk, W | 1 |
| Stanek, B | 1 |
| Maekawa, K | 1 |
| Fujimoto, T | 1 |
| Shiiki, H | 1 |
| Kanauchi, M | 1 |
| Fujii, Y | 1 |
| Dohi, K | 1 |
| Murata, K | 1 |
| Takayanagi, T | 1 |
| Campbell, N | 1 |
| Brant, R | 1 |
| Stalts, H | 1 |
| Stone, J | 1 |
| Mahallati, H | 1 |
| Yoshihara, F | 1 |
| Nishikimi, T | 1 |
| Kosakai, Y | 1 |
| Isobe, F | 1 |
| Matsuoka, H | 1 |
| Takishita, S | 1 |
| Kawashima, Y | 1 |
| Saito, Y | 1 |
| Kangawa, K | 1 |
| Fitts, DA | 1 |
| Lane, JR | 1 |
| Starbuck, EM | 1 |
| Li, CP | 1 |
| Tomiyama, H | 1 |
| Nakayama, T | 1 |
| Watanabe, G | 1 |
| Shiojima, K | 1 |
| Sakuma, Y | 1 |
| Yamamoto, A | 1 |
| Imai, Y | 1 |
| Yoshida, H | 1 |
| Doba, N | 1 |
| Rutgers, SR | 1 |
| Schweitzer, M | 1 |
| Northridge, DB | 1 |
| Newby, DE | 1 |
| Rooney, E | 1 |
| Norrie, J | 1 |
| Dargie, HJ | 1 |
| Westheim, AS | 1 |
| Bostrøm, P | 1 |
| Christensen, CC | 1 |
| Parikka, H | 1 |
| Rykke, EO | 1 |
| Toivonen, L | 1 |
| MacFadyen, R | 1 |
| Fraser, C | 1 |
| Robson, J | 1 |
| Morton, JJ | 1 |
| Junot, C | 1 |
| Ezan, E | 1 |
| Airaghi, L | 1 |
| Montori, D | 1 |
| Santambrogio, L | 1 |
| Miadonna, A | 1 |
| Tedeschi, A | 1 |
| Burnier, M | 1 |
| Monod, ML | 1 |
| Chioléro, A | 1 |
| Maillard, M | 1 |
| Nussberger, J | 1 |
| Brunner, HR | 1 |
| Park, CW | 1 |
| You, HY | 1 |
| Kim, YK | 1 |
| Chang, YS | 1 |
| Shin, YS | 1 |
| Hong, CK | 1 |
| Kim, YC | 1 |
| Bang, BK | 1 |
| Jhund, PS | 1 |
| Davie, AP | 1 |
| Adigun, AQ | 1 |
| Ajayi, AA | 1 |
| Redhammer, R | 1 |
| Kosinarova, V | 1 |
| Tamasova, M | 1 |
| Urban, S | 1 |
| Tsutsui, T | 1 |
| Tsutamoto, T | 1 |
| Maeda, K | 1 |
| Kinoshita, M | 1 |
| van de Ven, MJ | 1 |
| Colier, WN | 1 |
| van der Sluijs, MC | 1 |
| Oeseburg, B | 1 |
| Vis, P | 1 |
| Folgering, H | 1 |
| Yokoyama, H | 1 |
| Tsuji, Y | 1 |
| Gonzalez, JJ | 1 |
| Werk, EE | 1 |
| Thrasher, K | 1 |
| Behar, R | 1 |
| Loadholt, CB | 1 |
| Radó, JP | 2 |
| Szende, L | 1 |
| Szucs, L | 1 |
| Swartz, C | 1 |
| Kim, KE | 1 |
| Rothwell, RP | 1 |
| Prát, V | 1 |
| Bohuslav, V | 1 |
| Hatala, M | 1 |
| Liska, M | 1 |
| Sliz, K | 1 |
| Sidorenko, BA | 1 |
| Kharchenko, VI | 1 |
| Evsikov, EM | 1 |
| Ponomareva, AG | 1 |
| Gusarev, AF | 1 |
| Vorob'ev, VB | 1 |
| Thomsen, J | 1 |
| Bech, P | 1 |
| Szpirt, W | 1 |
| Sotorník, I | 1 |
| Stríbrná, J | 1 |
| Janata, V | 1 |
| Perchikova, GE | 1 |
| Tsibekmakher, TD | 1 |
| Shah, CV | 1 |
| Sterzel, RB | 1 |
| Nikulin, KG | 1 |
| Austin, SM | 1 |
| Schreiner, BF | 1 |
| Kramer, DH | 1 |
| Shah, PM | 1 |
| Yu, PN | 1 |
| Ferreira Filho, SR | 1 |
| Hatab, SA | 1 |
| Benchimol, C | 1 |
| Nascimento, LO | 1 |
| Saragoça, MA | 1 |
| Takahashi, H | 1 |
| Hifumi, S | 1 |
| Fujimura, M | 1 |
| Good, J | 1 |
| Frost, G | 1 |
| Oakley, CM | 1 |
| Flapan, AD | 2 |
| Davies, E | 2 |
| Waugh, C | 2 |
| Williams, BC | 2 |
| Shaw, TR | 2 |
| Edwards, CR | 2 |
| Yano, K | 1 |
| Matsumoto, Y | 1 |
| Hirata, M | 1 |
| Hirata, T | 1 |
| Hano, O | 1 |
| Mitsuoka, T | 1 |
| Hashiba, K | 1 |
| el-Zayadi, A | 1 |
| Mohran, Z | 1 |
| Hasseeb, N | 1 |
| Nagy, N | 1 |
| Dabbous, H | 1 |
| Vileisis, RA | 1 |
| Mizukami, K | 1 |
| Rush, MG | 1 |
| Engelhardt, B | 1 |
| Parker, RA | 1 |
| Hazinski, TA | 1 |
| Markiewicz, K | 2 |
| Dryjański, T | 2 |
| Cholewa, M | 2 |
| Gawor, Z | 2 |
| Kwon, NJ | 1 |
| Stolte, AL | 1 |
| Farina, JP | 1 |
| Nishioka, K | 1 |
| Katayama, I | 1 |
| Masuzawa, M | 1 |
| Yokozeki, H | 1 |
| Nishiyama, S | 1 |
| Crozier, IG | 1 |
| Richards, AM | 1 |
| Górski, L | 1 |
| Bechler-Lisińska, J | 1 |
| Broks-Bratkowska, B | 1 |
| Orynchak, Ma | 1 |
| Pankrat'ev, LM | 1 |
| Varshavskiĭ, VA | 1 |
| Richardson, A | 1 |
| Bayliss, J | 1 |
| Scriven, AJ | 1 |
| Parameshwar, J | 1 |
| Poole-Wilson, PA | 1 |
| Sutton, GC | 1 |
| Ezzedeen, F | 1 |
| Adelman, RD | 2 |
| Ahlfors, CE | 1 |
| Myracle, MR | 1 |
| McGahan, JP | 1 |
| Goetzman, BW | 1 |
| Modai, D | 1 |
| Cohen, N | 1 |
| Weissgarten, J | 1 |
| Segal, B | 1 |
| Pik, A | 1 |
| Eriksson, LO | 1 |
| Beermann, B | 1 |
| Kallner, M | 1 |
| van Meijel, JJ | 1 |
| Leshchinskiĭ, PM | 1 |
| Makarova, NA | 1 |
| Almazov, II | 1 |
| Arabidze, GG | 1 |
| Isshiki, A | 1 |
| Kono, K | 1 |
| Ueda, J | 1 |
| Kin, Y | 1 |
| Kubota, K | 1 |
| Ikeda, T | 1 |
| Daskalopoulos, G | 1 |
| Laffi, G | 1 |
| Morgan, T | 1 |
| Pinzani, M | 1 |
| Harley, H | 1 |
| Reynolds, T | 1 |
| Zipser, RD | 1 |
| Hutton, I | 1 |
| McGhie, AI | 1 |
| Martin, W | 1 |
| Tweddel, AC | 1 |
| Okada, Y | 1 |
| Minematsu, K | 1 |
| Miyashita, T | 1 |
| Yamaguchi, T | 1 |
| Pockros, PJ | 1 |
| Reynolds, TB | 1 |
| Nand, N | 1 |
| Gupta, MS | 1 |
| Sharma, M | 1 |
| Grigor'iants, RA | 1 |
| Gerasimova, VV | 1 |
| Scheen, AJ | 1 |
| Vancrombreucq, JC | 1 |
| Delarge, J | 1 |
| Luyckx, AS | 1 |
| Bhuttani, JK | 1 |
| Gupta, SP | 1 |
| Sakamoto, H | 1 |
| Umetani, N | 1 |
| Kobayashi, Y | 1 |
| Okubo, M | 1 |
| Marumo, F | 1 |
| Kikawada, R | 1 |
| McCann, EM | 1 |
| Lewis, K | 1 |
| Deming, DD | 1 |
| Donovan, MJ | 1 |
| Brady, JP | 1 |
| Ogata, H | 1 |
| Kawatsu, Y | 1 |
| Maruyama, Y | 1 |
| Machida, K | 1 |
| Haga, T | 1 |
| Mutina, ES | 1 |
| Fumagalli, G | 2 |
| Ferrara, A | 2 |
| Bonsignore, G | 1 |
| Bossi, R | 1 |
| Seedat, YK | 1 |
| Hannemann, HR | 1 |
| Coodley, EL | 1 |
| Garfield, A | 1 |
| Guiterrez, J | 1 |
| Platt, B | 1 |
| Rudyk, BI | 1 |
| Dzúriková, V | 1 |
| Brixová, E | 1 |
| Niederland, TR | 1 |
| Adam, W | 1 |
| Simpson, DP | 1 |
| Adrogue, HJ | 1 |
| Roehr, EE | 1 |
| Roncoroni, AJ | 1 |
| Riordan, JF | 1 |
| Sillett, RW | 1 |
| McNicol, MW | 1 |
| Klaus, D | 1 |
| Pupita, F | 1 |
| Bargnesi, P | 1 |
| Steinitz, L | 1 |
| Schreiter, G | 1 |
| Migone, L | 1 |
| Borghetti, A | 1 |
| Franchini, I | 1 |
| La Greca, G | 1 |
| Novarini, A | 1 |
| Gentili, G | 1 |
| Liberti, R | 1 |
| Borbély, L | 1 |
| Takó, J | 1 |
| Bános, C | 1 |
| Brass, H | 1 |
| Yamane, Y | 1 |
| Gutmann, FD | 1 |
| Shelp, WD | 1 |
| Rieselbach, RE | 1 |
| Beer, AM | 1 |
| Wegener, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diuretic Treatment in High Risk Decompensated Advanced Heart Failure. Bolus Intermittent Versus Continuous Infusion of Furosemide: a Randomized Controlled Trial.[NCT03592836] | Phase 3 | 80 participants (Actual) | Interventional | 2013-05-01 | Completed | ||
| Randomized, Open-Label, Blinded-Endpoint, Crossover, Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg, in Patients With Compensated Heart Failure (CHF).[NCT01549158] | Phase 4 | 8 participants (Actual) | Interventional | 2012-02-29 | Terminated (stopped due to Slow recruitment) | ||
| Safety and Efficacy of the Combination of Loop Diuretics With Thiazide-type Diuretics in Patients With Decompensated Heart Failure: a Double-blind, Randomized, Placebo-controlled Trial (CLOROTIC Trial).[NCT01647932] | Phase 3 | 232 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure - Prospective, Randomized, Open, Blinded Endpoint Trial[NCT01942109] | Phase 4 | 100 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | ||
| Prospective, Randomised, Open, Blinded-endpoint Study of Torasemide Prolonged Release vs Furosemide to Evaluate the Efficacy on Myocardial Fibrosis in Patients With Heart Failure[NCT00409942] | Phase 4 | 142 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury[NCT01098032] | Phase 3 | 294 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis[NCT02469597] | Phase 2 | 46 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| A Retrospective Chart Review Evaluating the Impact of Steroid, Diuretic, and Fluid Use Practice Trends in Extreme Premature Infants at Risk for Bronchopulmonary Dysplasia (BPD) at a Single Center Neonatal Intensive Care Unit[NCT04971694] | 175 participants (Anticipated) | Observational | 2021-09-08 | Recruiting | |||
| Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933] | Phase 2 | 34 participants (Actual) | Interventional | 2019-06-18 | Completed | ||
| Japanese Multicenter Evaluation of Long- Versus Short-acting Diuretics in Congestive Heart Failure[NCT00355667] | Phase 4 | 320 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| ESTIA: TorasEmide Induced Effect on Quality of Life and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone. Multicenter, Non-interventional, Prospective, Observational Clinical Study.[NCT06117722] | 210 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| The Role of Vasopressin Antagonism on Renal Sodium Handling[NCT03910231] | Phase 1 | 30 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| Urea for Chronic Hyponatremia: A Pilot Study[NCT04588207] | Phase 2 | 2 participants (Actual) | Interventional | 2021-12-28 | Terminated (stopped due to Unable to recruit participants) | ||
| Renal Insufficiency Following Contrast Media Administration Trial IV: Contrast Media Volume Control for Limiting Contrast-Induced Acute Kidney in Acute Coronary Syndrome.[NCT04714736] | 522 participants (Anticipated) | Interventional | 2020-02-10 | Recruiting | |||
| A Study to Evaluate the Effectiveness of Induced Diuresis With Matched Hydration Therapy Compared to Standard Overnight Hydration in the Prevention of Contrast Induced Nephropathy -MYTHOS Study[NCT00702728] | Phase 3 | 120 participants (Anticipated) | Interventional | 2008-06-30 | Recruiting | ||
| Renal Insufficiency Following Contrast Media Administration Trial III (REMEDIAL III): Renalguard System Versus Left-ventricular End-diastolic Pressure-guided Hydration in High-risk Patients for Contrast-induced Acute Kidney Injury[NCT02489669] | 700 participants (Anticipated) | Interventional | 2015-07-15 | Enrolling by invitation | |||
| Efficacy of Aquapheresis in Patients Treated as Outpatients With Decompensated Heart Failure at a Veterans Hospital[NCT04572867] | 0 participants (Actual) | Interventional | 2021-06-08 | Withdrawn (stopped due to Due to low enrollment, COVID-19 pandemic causing suspension of most outpatient elective procedures, and no protected research time, Dr. Gelzer Bell is unable to continue this study.) | |||
| Brain During Effort : Effects of Hypoxia With Respiratory Patients[NCT02854280] | 33 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| Evaluation of the Impact of the HL Natural, Inc. Tension Relief Product on the Reduction of Symptoms in Adults Who Suffer From Mild to Moderate Tension Headaches[NCT04091555] | 117 participants (Actual) | Interventional | 2019-10-16 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure will be the rate of development of CI-AKI in the 2 study arms (number of participants). CI-AKI is defined as an increase in the serum creatinine concentration >=0.3 mg/dL from the baseline value at 48 hours after administration of the contrast media or the need for dialysis. (NCT01098032)
Timeframe: at 48 hours following contrast exposure
| Intervention | participants (Number) |
|---|---|
| Systemic Alone Therapy Group | 146 |
| RenalGuard System Group | 146 |
(NCT02469597)
Timeframe: Participants will be followed for the duration of hospital stay up to 1 week
| Intervention | Days (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | 3.1 |
| Placebo | 3.0 |
(NCT02469597)
Timeframe: 2 hours after medication adminstration
| Intervention | Percentage change in oxygen saturation (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -0.14 |
| Placebo | 0.2 |
(NCT02469597)
Timeframe: 4 hours after medication adminstration
| Intervention | Percentage change in oxygen saturation (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -0.19 |
| Placebo | 0.29 |
(NCT02469597)
Timeframe: Within 72 hours of medication administration
| Intervention | participants (Number) |
|---|---|
| Single Dose of Furosemide | 0 |
| Placebo | 0 |
(NCT02469597)
Timeframe: 2 hours after medication adminstration
| Intervention | Percentage change in respiratory rate (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -3.7 |
| Placebo | -1.7 |
(NCT02469597)
Timeframe: 4 hours after medication adminstration
| Intervention | Percentage change in respiratory rate (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -2.8 |
| Placebo | -5.4 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -3.4 |
| Treatment Grup | -13.5 |
Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.15 |
| Treatment Grup | 2.55 |
Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of ECW/TBW (Mean) |
|---|---|
| Placebo | -0.24 |
| Treatment Grup | -2.92 |
decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -5.4 |
| Treatment Grup | -18.1 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -10 |
| Treatment Grup | -26.1 |
Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of sodium excreted (Mean) |
|---|---|
| Placebo | -0.348 |
| Treatment Grup | 0.598 |
Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.075 |
| Treatment Grup | -4.36 |
25 reviews available for furosemide and Chronic Illness
| Article | Year |
|---|---|
Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Topics: Abruptio Placentae; Amlodipine; Antihypertensive Agents; Atenolol; Cesarean Section; Chronic Disease | 2020 |
[The Role of Pharmacists in Home Medical Care of Patients with Heart Failure].
Topics: Catecholamines; Chronic Disease; Dobutamine; Furosemide; Heart Failure; Home Care Services; Humans; | 2020 |
Updates in opioid and nonopioid treatment for chronic breathlessness.
Topics: Analgesics, Opioid; Anti-Anxiety Agents; Breathing Exercises; Chronic Disease; Dose-Response Relatio | 2019 |
Ten pitfalls in the proper management of patients with hyponatremia.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Chronic Disease; Diuretics; Drug Dosage Ca | 2016 |
[Etiology, diagnostics and therapy of hyponatremias].
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Blood Volume; Brain D | 2008 |
[Update: prolonged-release torasemide].
Topics: Animals; Chronic Disease; Delayed-Action Preparations; Diuretics; Furosemide; Heart Failure; Humans; | 2010 |
Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure?
Topics: Adult; Chronic Disease; Disease Management; Diuretics; Female; Furosemide; Heart Failure; Hospice Ca | 2011 |
Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design.
Topics: Acetylcysteine; Acute Kidney Injury; Biomarkers; Chi-Square Distribution; Chronic Disease; Contrast | 2011 |
Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.
Topics: Age Factors; Chronic Disease; Diuretics; Furosemide; Humans; Infant, Newborn; Infant, Premature; Inf | 2011 |
Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.
Topics: Age Factors; Chronic Disease; Diuretics; Furosemide; Humans; Infant, Newborn; Infant, Premature; Inf | 2011 |
Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.
Topics: Age Factors; Chronic Disease; Diuretics; Furosemide; Humans; Infant, Newborn; Infant, Premature; Inf | 2011 |
Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.
Topics: Age Factors; Chronic Disease; Diuretics; Furosemide; Humans; Infant, Newborn; Infant, Premature; Inf | 2011 |
[Treatment of bone disease in chronic kidney disease and in renal transplant recipients under K/DOQI clinical practice guidelines].
Topics: Bone Density; Bone Diseases, Metabolic; Calcitonin; Chronic Disease; Diphosphonates; Epoxy Compounds | 2004 |
Aerosolized diuretics for preterm infants with (or developing) chronic lung disease.
Topics: Aerosols; Chronic Disease; Diuretics; Furosemide; Humans; Infant, Newborn; Infant, Premature; Infant | 2006 |
Management of hypertension in chronic kidney disease.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Dise | 2006 |
Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Chromosome | 2007 |
[Analysis of causes of decreased reactivity of the kidney to furosemide in newborn infants and children with chronic glomerulonephritis].
Topics: Adolescent; Age Factors; Child; Child, Preschool; Chronic Disease; Drug Resistance; Furosemide; Glom | 1983 |
Anti-hypertensive drugs in the pregnant patient.
Topics: Antihypertensive Agents; Chronic Disease; Clonidine; Diazoxide; Diuretics; Female; Fetus; Furosemide | 1980 |
[Treatment of chronic pulmonary heart disease].
Topics: Bloodletting; Chronic Disease; Digitalis Glycosides; Furosemide; Humans; Myocardial Contraction; Oxy | 1980 |
Recurrent and chronic leg ulcers secondary to furosemide-induced bullous pemphigoid.
Topics: Aged; Aged, 80 and over; Chronic Disease; Female; Furosemide; Humans; Leg Ulcer; Male; Pemphigoid, B | 1995 |
The hyponatremic patient: practical focus on therapy.
Topics: Acute Disease; Blood Volume; Body Water; Brain Edema; Chronic Disease; Demyelinating Diseases; Diure | 1997 |
Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.
Topics: Chronic Disease; Diuretics; Furosemide; Humans; Infant, Newborn; Infant, Premature; Infant, Prematur | 2000 |
Aerosolized diuretics for preterm infants with (or developing) chronic lung disease.
Topics: Aerosols; Chronic Disease; Diuretics; Furosemide; Humans; Infant, Newborn; Infant, Premature; Infant | 2000 |
Chronic systemic capillary leak syndrome. Report of a case and review of the literature.
Topics: Capillary Leak Syndrome; Chronic Disease; Diagnosis, Differential; Diuretics; Edema; Female; Furosem | 2000 |
Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.
Topics: Chronic Disease; Diuretics; Furosemide; Humans; Infant, Newborn; Infant, Premature; Infant, Prematur | 2000 |
Aerosolized diuretics for preterm infants with (or developing) chronic lung disease.
Topics: Aerosols; Chronic Disease; Diuretics; Furosemide; Humans; Infant, Newborn; Infant, Premature; Infant | 2001 |
Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.
Topics: Chronic Disease; Diuretics; Furosemide; Humans; Infant, Newborn; Infant, Premature; Infant, Prematur | 2002 |
[Treatment of bronchial asthma].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Bronchitis; C | 1974 |
59 trials available for furosemide and Chronic Illness
| Article | Year |
|---|---|
Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients.
Topics: Administration, Inhalation; Adult; Aerosols; Aged; Aged, 80 and over; Asthma; Chronic Disease; Cross | 2020 |
Shenfu injection combined with furosemide in the treatment of chronic heart failure in patients with coronary heart disease: A protocol of randomized controlled trial.
Topics: Chronic Disease; Coronary Disease; Diuretics; Drug Therapy, Combination; Drugs, Chinese Herbal; Furo | 2021 |
Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study.
Topics: Acetazolamide; Administration, Intravenous; Aged; Aged, 80 and over; Chronic Disease; Diuretics; Dos | 2017 |
Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure-bolus intermittent vs. continuous infusion of furosemide: a randomized controlled trial.
Topics: Aged; Central Venous Pressure; Chronic Disease; Double-Blind Method; Drug Administration Schedule; D | 2020 |
Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Disease Progression; Diuretics; Edema; Fema | 2014 |
Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure.
Topics: Aged; Blood Glucose; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Furosemide; H | 2014 |
Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.
Topics: Aged; Aged, 80 and over; Chemistry, Pharmaceutical; Chronic Disease; Cross-Over Studies; Delayed-Act | 2015 |
Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure.
Topics: Aged; Aged, 80 and over; Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, | 2015 |
Rationale and Design of the "Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) Trial:" A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effect of Combin
Topics: Chronic Disease; Diuretics; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Furosemi | 2016 |
Changes in brain natriuretic peptide in chronic heart failure patients treated with long-acting versus short-acting loop diuretics: J-MELODIC subanalysis.
Topics: Aged; Aged, 80 and over; Biomarkers; Chronic Disease; Echocardiography; Female; Furosemide; Heart Fa | 2017 |
The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial.
Topics: Biomarkers; Chronic Disease; Clinical Protocols; Echocardiography; Electrocardiography, Ambulatory; | 2017 |
Influence of spironolactone therapy on thiamine blood levels in patients with heart failure.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Chronic Disease; Cross-Sectional Studies; Diuretic | 2008 |
TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure.
Topics: Chronic Disease; Collagen Type I; Delayed-Action Preparations; Diuretics; Female; Fibrosis; Furosemi | 2009 |
Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design.
Topics: Acetylcysteine; Acute Kidney Injury; Biomarkers; Chi-Square Distribution; Chronic Disease; Contrast | 2011 |
Comparative analysis of the therapeutic effects of long-acting and short-acting loop diuretics in the treatment of chronic heart failure using (123)I-metaiodobenzylguanidine scintigraphy.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Chronic Disease; Cross-Over Studies; Female; | 2011 |
Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study.
Topics: Aged; Biomarkers; Chronic Disease; Delayed-Action Preparations; Diuretics; Endpoint Determination; F | 2011 |
A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease.
Topics: Aged; Anthropology; Biological Availability; Blood Pressure; Chronic Disease; Diet Records; Diuretic | 2012 |
Comparative study of therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure (COLD-CHF).
Topics: Aged; Atrial Natriuretic Factor; Biomarkers; Chronic Disease; Delayed-Action Preparations; Echocardi | 2012 |
Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Chronic Disease; Disease-Free Survival; Female; Fu | 2012 |
Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival.
Topics: Aged; Calcium; Chronic Disease; Data Interpretation, Statistical; Diuretics; Drug Administration Sch | 2012 |
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arg | 2003 |
Treatment of recurrent chronic hyperplastic sinusitis with nasal polyposis.
Topics: Administration, Intranasal; Adult; Anti-Inflammatory Agents; Chronic Disease; Diuretics; Female; Fur | 2003 |
Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Chronic Disease; Diuretics; Female; Follow-Up Studies | 2003 |
Increased urinary aquaporin-2 excretion in response to furosemide in patients with chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Aquaporin 2; Arginine Vasopressin; Atrial Natriureti | 2006 |
Xamoterol improves the control of chronic atrial fibrillation in elderly patients.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Atrial Fibrillation; Chronic Disease; Cross-Over | 1995 |
Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Chronic Disease; Coronary Disease; Cro | 1995 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Reversal of bronchial obstruction in children with mild stable asthma by aerosolized furosemide.
Topics: Administration, Inhalation; Adolescent; Albuterol; Analysis of Variance; Asthma; Child; Chronic Dise | 1994 |
Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result.
Topics: Aged; Chronic Disease; Exercise Test; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Injec | 1994 |
Captopril treatment of chronic heart failure in the very old.
Topics: Aged; Aged, 80 and over; Captopril; Cardiac Output, Low; Chronic Disease; Digoxin; Double-Blind Meth | 1994 |
Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure.
Topics: Administration, Oral; Aged; Blood Pressure; Captopril; Chronic Disease; Diuresis; Double-Blind Metho | 1993 |
Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide.
Topics: Aged; Chronic Disease; Edema; Female; Furosemide; Heart Failure; Hemofiltration; Humans; Male; Middl | 1996 |
The effect of hypoxaemia on drug disposition in chronic respiratory failure.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Biological Availability; Chronic Disease; Cros | 1996 |
Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Drug S | 1996 |
Changes in body water compartments with diuretic therapy in infants with chronic lung disease.
Topics: Body Water; Chronic Disease; Diuretics; Drug Therapy, Combination; Extracellular Space; Furosemide; | 1997 |
The effect of aerosolized furosemide in infants with chronic lung disease.
Topics: Administration, Inhalation; Aerosols; Bronchodilator Agents; Chronic Disease; Cross-Over Studies; Do | 1997 |
Fluctuations in blood lipid levels during furosemide therapy: a randomized, double-blind, placebo-controlled crossover study.
Topics: Aged; Apolipoproteins; Cholesterol; Chronic Disease; Cross-Over Studies; Diuretics; Double-Blind Met | 1998 |
Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure.
Topics: Blood Pressure; Cardiac Output; Chronic Disease; Cross-Over Studies; Diuretics; Echocardiography, Do | 1999 |
Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure.
Topics: Atrial Natriuretic Factor; Chronic Disease; Diuretics; Double-Blind Method; Exercise Test; Furosemid | 1999 |
Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure.
Topics: Adolescent; Adult; Aged; Aldosterone; Antihypertensive Agents; Chronic Disease; Diuretics; Double-Bl | 1999 |
Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Chronic D | 1999 |
Renal sodium handling in acute and chronic salt loading/depletion protocols: the confounding influence of acute water loading.
Topics: Acute Disease; Adult; Blood Pressure; Chronic Disease; Diet, Sodium-Restricted; Diuretics; Furosemid | 2000 |
Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure.
Topics: Aged; Aspirin; Chronic Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind M | 2001 |
[Therapeutic use of amiloride and its combinations with hydrochlorothiazide and furosemide in chronic circulatory insufficiency].
Topics: Adult; Aged; Amiloride; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Diuresis | 1978 |
[Captopril in the treatment of patients with congestive heart failure. Its bicycle ergometry evaluation].
Topics: Analysis of Variance; Captopril; Chronic Disease; Digitoxin; Double-Blind Method; Drug Therapy, Comb | 1992 |
The renal effects of dopamine and dobutamine in stable chronic heart failure.
Topics: Aged; Chronic Disease; Diuresis; Dobutamine; Dopamine; Drug Interactions; Drug Therapy, Combination; | 1992 |
Posture determines the nature of the interaction between angiotensin converting enzyme inhibitors and loop diuretics in patients with chronic cardiac failure.
Topics: Aged; Captopril; Chronic Disease; Creatinine; Drug Interactions; Drug Therapy, Combination; Furosemi | 1991 |
Short-term course of corticosteroids in the treatment of resistant ascites complicating schistosomal liver disease.
Topics: Adolescent; Adult; Aged; Ascites; Chronic Disease; Diuresis; Drug Therapy, Combination; Female; Furo | 1991 |
Furosemide effect on mineral status of parenterally nourished premature neonates with chronic lung disease.
Topics: Adenosine Monophosphate; Calcium; Chronic Disease; Furosemide; Homeostasis; Humans; Hyperparathyroid | 1990 |
Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia.
Topics: Airway Resistance; Bronchopulmonary Dysplasia; Calcium; Chronic Disease; Clinical Trials as Topic; D | 1990 |
[Evaluation of the effect of nifedipine in patients with chronic congestive heart failure].
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Digoxin; Diuresis; Female; Furosemide; Heart | 1989 |
Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure.
Topics: Amiloride; Captopril; Chronic Disease; Clinical Trials as Topic; Diuretics; Double-Blind Method; Dru | 1987 |
Renal function and tubular transport effects of sulindac and naproxen in chronic heart failure.
Topics: Aged; Biological Transport; Body Water; Chronic Disease; Electrolytes; Female; Furosemide; Glomerula | 1987 |
A comparison of intravenous elantan and frusemide in patients with chronic cardiac failure.
Topics: Blood Pressure; Cardiac Output; Chronic Disease; Coronary Circulation; Furosemide; Heart Failure; Hu | 1987 |
Furosemide supplemented blood transfusion in cases of chronic severe anemia.
Topics: Adult; Anemia; Blood Proteins; Blood Transfusion; Chronic Disease; Furosemide; Heart Rate; Hemoglobi | 1986 |
Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study.
Topics: Aged; Calcium; Chronic Disease; Creatinine; Diuretics; Double-Blind Method; Drug Evaluation; Electro | 1986 |
Controlled trial of furosemide therapy in infants with chronic lung disease.
Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Furosemide; Human | 1985 |
The significance of plasma renin determinations for differential diagnosis of hypertensiony.
Topics: Chronic Disease; Clinical Trials as Topic; Diagnosis, Differential; Diazoxide; Diet, Sodium-Restrict | 1970 |
Willow bark extract (Salicis cortex) for gonarthrosis and coxarthrosis--results of a cohort study with a control group.
Topics: Aged; Chronic Disease; Female; Humans; Male; Middle Aged; Osteoarthritis, Hip; Osteoarthritis, Knee; | 2008 |
117 other studies available for furosemide and Chronic Illness
| Article | Year |
|---|---|
Response letter to Shetty and Shetty's reply about DRAIN trial.
Topics: Chronic Disease; Diuretics; Drainage; Furosemide; Heart Failure; Humans | 2020 |
Diabetic patients need higher furosemide doses: a report on acute and chronic heart failure patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Diabetes Mellitus; Drug Resistance; Female; | 2020 |
Rethinking furosemide use for infants with bronchopulmonary dysplasia.
Topics: Bronchopulmonary Dysplasia; Chronic Disease; Furosemide; Hospitalization; Humans; Infant, Newborn; I | 2020 |
Intensification of pharmacological decongestion but not the actual daily loop diuretic dose predicts worse chronic heart failure outcome: insights from TIME-CHF.
Topics: Aged; Aged, 80 and over; Chronic Disease; Disease Progression; Female; Furosemide; Germany; Heart Fa | 2021 |
Prognostic Effect of the Dose of Loop Diuretic Over 5 Years in Chronic Heart Failure.
Topics: Aged; Chronic Disease; Cohort Studies; Diuretics; Dose-Response Relationship, Drug; Female; Furosemi | 2017 |
Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzym | 2019 |
Outdoor temperature and survival benefit of empiric potassium in users of furosemide in US Medicaid enrollees: a cohort study.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Chronic Disease; Cross-Sectional Studies; Diur | 2019 |
Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Chronic Disease; Dose-Response Relationship, D | 2013 |
Management of acute heart failure and the effect of systolic blood pressure on the use of intravenous therapies.
Topics: Acute Disease; Aged; Analgesics, Opioid; Blood Pressure; Cardiotonic Agents; Chronic Disease; Diseas | 2013 |
Sclederma of Poria cocos exerts its diuretic effect via suppression of renal aquaporin-2 expression in rats with chronic heart failure.
Topics: Administration, Oral; Animals; Aquaporin 2; Arginine Vasopressin; Chronic Disease; Disease Models, A | 2014 |
Poor concordance between different definitions of worsening renal function in patients with acute exacerbation of chronic heart failure: a retrospective study.
Topics: Acute Disease; Administration, Intravenous; Aged; Aged, 80 and over; Chronic Disease; Creatinine; Di | 2016 |
[Diuretic-Abuse in Chronic Bulimia Nervosa--Case Report and Clinical Management].
Topics: Adult; Bulimia Nervosa; Chronic Disease; Diuretics; Female; Furosemide; Humans; Substance-Related Di | 2015 |
Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.
Topics: Aged; Aged, 80 and over; Chronic Disease; Dose-Response Relationship, Drug; Female; Furosemide; Glom | 2016 |
A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2016 |
Warning on diuretic use.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Cohort Studies; | 2010 |
Evolution of renal oxygen content measured by BOLD MRI downstream a chronic renal artery stenosis.
Topics: Animals; Chronic Disease; Diuretics; Furosemide; Hypoxia; Magnetic Resonance Imaging; Male; Oxygen; | 2011 |
In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
Topics: Aged; Aged, 80 and over; Algorithms; Analysis of Variance; Biomarkers; Case-Control Studies; Chronic | 2011 |
Prognostic implications of diuretic dose in chronic heart failure.
Topics: Aged; Aged, 80 and over; Chronic Disease; Cohort Studies; Diuretics; Dose-Response Relationship, Dru | 2011 |
Furosemide induces mortality in a rat model of chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Chronic Disease; Disease Models, Animal; Diuretic | 2012 |
Amlodipine and loop diuretics as the second anti-hypertensive medication for the treatment of hypertension with chronic kidney diseases.
Topics: Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2011 |
Furosemide in chronic advanced heart failure: intimate friend or cunning foe?
Topics: Animals; Chronic Disease; Diuretics; Furosemide; Heart Failure; Humans; Severity of Illness Index | 2011 |
Torasemide in chronic heart failure: results of the TORIC study.
Topics: Aged; Chronic Disease; Diuretics; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Pota | 2002 |
[Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide?].
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Cost-Benefit Analysis; Diuretics; Female; Furosemid | 2002 |
[Which loop diuretic for heart failure? For prognosis the choices are not all the same].
Topics: Chronic Disease; Diuretics; Furosemide; Heart Failure; Humans; Prognosis; Randomized Controlled Tria | 2002 |
Bedside B-type natriuretic peptide and functional capacity in chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzy | 2003 |
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Chronic Disease; Disease Models, Animal; Diuretic | 2003 |
[Diuretics in heart failure. Fewer electrolyte disorders -- better prognosis].
Topics: Chronic Disease; Clinical Trials as Topic; Diuretics; Furosemide; Heart Failure; Humans; Hypokalemia | 2003 |
Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study.
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Cohort Studie | 2004 |
Management of hypertension in patients with CKD: differences between primary and tertiary care settings.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2005 |
Dissociation between improvement in left ventricular performance and functional class in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Chr | 2005 |
Bloodletting-induced cardiomyopathy: reversible cardiac hypertrophy in severe chronic anaemia from long-term bloodletting with cupping.
Topics: Aged; Anemia, Iron-Deficiency; Angiotensin-Converting Enzyme Inhibitors; Cardiomegaly; Chronic Disea | 2008 |
Acute haemodynamic, hormonal and electrolyte effects and short-term clinical response to enalapril in heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Blood Pressure; Chronic Disease; Electrolytes; Enalapril; Female; | 1983 |
Chronic aortitis following furosemide therapy.
Topics: Adult; Aorta, Thoracic; Aortitis; Chronic Disease; Furosemide; Humans; Retrospective Studies | 1984 |
Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia.
Topics: Airway Resistance; Bronchopulmonary Dysplasia; Chronic Disease; Furosemide; Humans; Infant, Newborn; | 1983 |
Cardiovascular responses to asphyxial challenge in chronically hypokalemic dogs.
Topics: Anesthesia, General; Animals; Asphyxia; Chronic Disease; Dogs; Furosemide; Hemodynamics; Hypokalemia | 1983 |
[Effect of a combination of furosemid retard and triamteren in congestive edema].
Topics: Chronic Disease; Delayed-Action Preparations; Female; Furosemide; Humans; Male; Middle Aged; Pressur | 1984 |
A severe bullous eruption occurring in a patient with chronic active hepatitis and glomerulonephritis.
Topics: Adult; Chronic Disease; Furosemide; Glomerulonephritis; Hepatitis; Humans; Male; Metolazone; Nitraze | 1980 |
Inappropriate secretion of antidiuretic hormone treated with frusemide.
Topics: Chronic Disease; Furosemide; Humans; Inappropriate ADH Syndrome; Sodium Chloride | 1982 |
Furosemide-induced increase in urinary and peritoneal excretion of uric acid during peritoneal dialysis in patients with chronic uremia.
Topics: Chronic Disease; Furosemide; Humans; Peritoneal Dialysis; Uremia; Uric Acid | 1983 |
Catecholamines levels and parotid secretion in children with chronic atopic dermatitis.
Topics: Catecholamines; Child; Child, Preschool; Chronic Disease; Dermatitis, Atopic; Dopamine; Epinephrine; | 1982 |
[Effect of lasix on central and peripheral circulation in patients with chronic circulatory insufficiency].
Topics: Adolescent; Adult; Blood; Cardiac Output; Cardiomyopathies; Chronic Disease; Female; Furosemide; Hea | 1982 |
Nutritional rickets in 2 very low birthweight infants with chronic lung disease.
Topics: Bicarbonates; Bronchial Diseases; Calcium; Chronic Disease; Female; Furosemide; Humans; Infant; Infa | 1980 |
Systolic time intervals in chronic severe anaemia and effect of diuretic and digitalis.
Topics: Adult; Anemia; Chronic Disease; Digoxin; Furosemide; Humans; Male; Middle Aged; Myocardial Contracti | 1981 |
[Influence of furosemide on the acidifying dysfunction of renal tubular acidosis].
Topics: Acidosis, Renal Tubular; Chronic Disease; Diuresis; Furosemide; Humans; Hydrogen-Ion Concentration; | 1980 |
[Bacteriologic study of the urine of pyelonephritis patients following administration of saluretics].
Topics: Anti-Infective Agents, Urinary; Bacteria; Bacteriuria; Chronic Disease; Furosemide; Humans; Microbia | 1980 |
Inappropriate antidiuretic hormone secretion.
Topics: Acute Disease; Butorphanol; Chronic Disease; Demeclocycline; Drinking Behavior; Furosemide; Humans; | 1994 |
The effect of chronic sodium depletion on renal function in conscious rats.
Topics: Absorption; Animals; Chronic Disease; Diet, Sodium-Restricted; Extracellular Space; Furosemide; Glom | 1994 |
[Effects of inhaled furosemide after indomethacin premedication on bronchial hyperresponsiveness in patients with chronic congestive heart failure].
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Bronchial Hyperreactivity; Chronic Disease; Fem | 1994 |
Endogenous prostaglandin E2 mediates inhibition of rat thick ascending limb Cl reabsorption in chronic hypercalcemia.
Topics: Alkaloids; Animals; Biological Transport, Active; Chlorides; Chronic Disease; Colforsin; Cyclic AMP; | 1993 |
[Non-invasive determination of the quantity of pleural effusion and evaluation of the beneficial effect of pleuracentesis in patients with acute exacerbation of chronic congestive heart failure].
Topics: Aged; Chronic Disease; Diuretics; Furosemide; Heart Failure; Humans; Middle Aged; Paracentesis; Pleu | 1997 |
[High-dose furosemide: a new cause of chronic pancreatitis?].
Topics: Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Furosemide; Humans; Male; Middle Aged; | 1997 |
Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables.
Topics: Adrenergic Agonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiotonic | 1998 |
[A case of Bartter's syndrome with chronic renal failure due to chronic interstitial nephritis].
Topics: Bartter Syndrome; Chronic Disease; Diuretics; Female; Furosemide; Humans; Hypokalemia; Kidney Failur | 1998 |
Atrial natriuretic peptide secretion and body fluid balance after bilateral atrial appendectomy by the maze procedure.
Topics: Atrial Fibrillation; Atrial Natriuretic Factor; Body Fluids; Cardiac Surgical Procedures; Chronic Di | 1998 |
Drinking and blood pressure during sodium depletion or ANG II infusion in chronic cholestatic rats.
Topics: Angiotensin II; Animals; Appetite; Blood Pressure; Body Weight; Cholestasis; Chronic Disease; Common | 1999 |
Chronic eosinophilic pneumonia with pleural effusion.
Topics: Aged; Biopsy; Captopril; Chronic Disease; Dyspnea; Female; Furosemide; Heart Failure; Humans; Lung; | 1999 |
Chronic tubulointerstitial nephritis and distal renal tubular acidosis in a patient with frusemide abuse.
Topics: Acidosis, Renal Tubular; Chronic Disease; Furosemide; Humans; Nephritis, Interstitial | 2001 |
The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthropometry; Body Mass Index; Cachexia; Car | 2001 |
[The furosemide test in diagnosis of the cause of bronchial obstruction].
Topics: Administration, Inhalation; Asthma; Bronchi; Bronchitis; Chronic Disease; Female; Furosemide; Humans | 2001 |
Comparison of neurohumoral effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure.
Topics: Administration, Oral; Aged; Chi-Square Distribution; Chronic Disease; Diuretics; Dosage Forms; Femal | 2001 |
Effects of acetazolamide and furosemide on ventilation and cerebral blood volume in normocapnic and hypercapnic patients with COPD.
Topics: Acetazolamide; Administration, Oral; Alkalosis; Blood Volume; Carbon Dioxide; Cerebrovascular Circul | 2002 |
Diuretic Doppler ultrasonography in chronic unilateral partial ureteric obstruction in dogs.
Topics: Animals; Blood Flow Velocity; Chronic Disease; Contrast Media; Diuretics; Diuretics, Osmotic; Dogs; | 2002 |
Renin aldosterone system and potassium levels in chronic lead intoxication.
Topics: Adult; Aged; Aldosterone; Chronic Disease; Creatinine; Edetic Acid; Female; Furosemide; Humans; Hype | 1979 |
Hyperkalemia unresponsive to massive doses of aldosterone and renal tubular acidosis in a patient with chronic interstitial nephritis: clinical and experimental studies.
Topics: Acidosis, Renal Tubular; Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Chronic Disease; | 1976 |
Treatment of complicated hypertension.
Topics: Acute Disease; Cerebral Hemorrhage; Cerebrovascular Disorders; Chronic Disease; Coronary Disease; Di | 1977 |
Pulmonary oedema.
Topics: Acute Disease; Aminophylline; Chronic Disease; Furosemide; Humans; Morphine; Pulmonary Edema | 1979 |
[Ourexperiences with clinical methods for localization of urinary tract infections].
Topics: Adult; Antibodies, Bacterial; Antibody Formation; Bacteriuria; Chronic Disease; Female; Fluorescent | 1977 |
[Various causes of refractory course of chronic cardiac insufficiency].
Topics: Adult; Aged; Blood Coagulation; Chronic Disease; Female; Furosemide; Heart Failure; Heparin; Humans; | 1978 |
[Acoustic-vestibular symptoms in chronic renal insufficiency].
Topics: Adult; Aminoglycosides; Chronic Disease; Drug Interactions; Female; Furosemide; Hearing Disorders; H | 1976 |
[Effect of furosemide on residual nephrons in patients with chronic glomerulonephritis].
Topics: Adult; Chronic Disease; Female; Furosemide; Glomerular Filtration Rate; Glomerulonephritis; Humans; | 1977 |
[Treatment of refractory chronic circulatory insufficiency].
Topics: Adult; Aged; Benzothiadiazines; Cardiac Glycosides; Cardiomyopathies; Chronic Disease; Coronary Dise | 1976 |
Management of chronic cor-pulmonale.
Topics: Blood Gas Analysis; Chronic Disease; Digitalis Glycosides; Furosemide; Humans; Lung; Oxygen Inhalati | 1976 |
[Treatment of reversible, uremia-inducing factors in chronic interstitial nephritis].
Topics: Blood Volume; Central Venous Pressure; Chronic Disease; Furosemide; Humans; Kidney; Nephritis, Inter | 1975 |
[Principles of current therapy of acute and chronic pneumonia].
Topics: Acute Disease; Aminophylline; Anti-Bacterial Agents; Blood Coagulation; Body Temperature; Chronic Di | 1975 |
The acute hemodynamic effects of ethacrynic acid and furosemide in patients with chronic postcapillary pulmonary hypertension.
Topics: Adult; Blood Pressure; Blood Volume; Body Fluids; Cardiac Output; Chronic Disease; Ethacrynic Acid; | 1976 |
[Effects of inhaled and intravenous furosemide on bronchial hyperresponsiveness in patients with chronic congestive heart failure].
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Bronchial Hyperreactivity; Chronic Disea | 1992 |
The influence of posture on the response to loop diuretics in patients with chronic cardiac failure is reduced by angiotensin converting enzyme inhibition.
Topics: Adult; Aged; Aged, 80 and over; Cardiac Output, Low; Chronic Disease; Diuresis; Enalapril; Furosemid | 1992 |
Influence of sympathetic nerve activity on ventricular arrhythmogenicity in the dog with chronic hypokalemia.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Chronic Disease; Dogs; Electrophysiology; | 1991 |
[Glomerular function and urine acidification in chronic renal diseases].
Topics: Acidosis, Renal Tubular; Bicarbonates; Chronic Disease; Furosemide; Glomerular Filtration Rate; Glom | 1990 |
[Changes in left-ventricular function in chronic congestive heart failure treated with digoxin, furosemide and vasodilators].
Topics: Adult; Aged; Chronic Disease; Digoxin; Drug Interactions; Drug Therapy, Combination; Furosemide; Hea | 1990 |
Hypokalemia in rats produces resistance to dysrhythmias under halothane anesthesia.
Topics: Acute Disease; Anesthesia, Inhalation; Animals; Arrhythmias, Cardiac; Cardiac Complexes, Premature; | 1989 |
Drug-induced chronic pigmented purpura.
Topics: Aged; Chlordiazepoxide; Chronic Disease; Female; Furosemide; Humans; Male; Middle Aged; Nitroglyceri | 1989 |
Inefficacy of daily single bolus dose atrial natriuretic factor in chronic congestive heart failure.
Topics: Aged; Atrial Natriuretic Factor; Chronic Disease; Drug Administration Schedule; Electrocardiography, | 1989 |
[Effect of digoxin, furosemide and finoptin on the central hemodynamics in hypertension].
Topics: Aged; Chronic Disease; Digoxin; Drug Evaluation; Drug Therapy, Combination; Female; Furosemide; Hear | 1989 |
[Effect of furosemide on proteinuria in patients suffering from amyloidosis and chronic nephritis with various tubulostromal lesions of the kidneys].
Topics: Amyloidosis; Chronic Disease; Furosemide; Glomerulonephritis; Humans; Kidney; Nephritis; Nephrotic S | 1989 |
Renal calcification in preterm infants: pathophysiology and long-term sequelae.
Topics: Birth Weight; Calcium; Chronic Disease; Follow-Up Studies; Furosemide; Humans; Infant, Newborn; Infa | 1988 |
Ultrasound diagnosis of renal calcification in infants on chronic furosemide therapy.
Topics: Bone and Bones; Bone Diseases; Calcinosis; Chronic Disease; Furosemide; Humans; Infant; Infant, Low | 1986 |
Symptomatic renal artery stenosis superimposed on chronic glomerulonephritis.
Topics: Antihypertensive Agents; Cardiomegaly; Chlorthalidone; Chronic Disease; Creatinine; Furosemide; Glom | 1985 |
High-dose furosemide in the treatment of refractory congestive heart failure.
Topics: Aged; Aged, 80 and over; Chronic Disease; Creatinine; Drug Administration Schedule; Female; Furosemi | 1988 |
[Clinical effectiveness of minoxidil in patients with severe forms of arterial hypertension].
Topics: Adult; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Furosemide; Humans; Hype | 1988 |
[Anesthetic management of a patient with pseudo Batter's syndrome caused by the long-term use of furosemide].
Topics: Adult; Anesthesia; Chronic Disease; Female; Furosemide; Hematoma, Epidural, Cranial; Humans; Hypokal | 1987 |
Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites.
Topics: Ascites; Blood Pressure; Chronic Disease; Furosemide; Hemodynamics; Humans; Inulin; Kidney; Liver Di | 1987 |
[Effect of sodium load and furosemide administration on the chronic type of the syndrome of inappropriate secretion of antidiuretic hormone].
Topics: Administration, Oral; Chronic Disease; Furosemide; Humans; Inappropriate ADH Syndrome; Male; Middle | 1987 |
Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema.
Topics: Amiloride; Ascites; Body Weight; Chronic Disease; Diuresis; Edema; Electrolytes; Furosemide; Humans; | 1986 |
[Furotriam in chronic circulatory failure].
Topics: Adult; Atrial Fibrillation; Chronic Disease; Diuresis; Drug Combinations; Drug Evaluation; Female; F | 1986 |
Blood transfusion in cases of chronic severe anaemia--how safe?
Topics: Adult; Anemia; Blood Transfusion; Chronic Disease; Furosemide; Humans; Pulmonary Wedge Pressure; Saf | 1986 |
[A case of reversible hyperkalemic distal renal tubular acidosis associated with chronic pyelonephritis].
Topics: Acidosis, Renal Tubular; Chronic Disease; Female; Furosemide; Humans; Hyperkalemia; Kidney Tubules, | 1986 |
Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.
Topics: Administration, Oral; Aged; Biological Availability; Chronic Disease; Female; Food; Furosemide; Gluc | 1985 |
[In vitro effects of saluretics, osmotic pressure and the acidity of the medium on the evaluated globular volume in chronic bronchopneumopathies by means of microhematocrit].
Topics: Acid-Base Equilibrium; Benzothiadiazines; Blood Volume; Chronic Disease; Diuretics; Furosemide; Hema | 1974 |
[Behavior of hematocrit values in chronic bronchopneumatic patients during administration of saluretics].
Topics: Adult; Body Water; Chronic Disease; Diuretics; Furosemide; Hematocrit; Humans; Middle Aged; Respirat | 1974 |
High-dose furosemide (Lasix) in renal insufficiency.
Topics: Acute Disease; Acute Kidney Injury; Adult; Chronic Disease; Diet, Sodium-Restricted; Female; Furosem | 1972 |
[Diuretic treatment of heart failure].
Topics: Bloodletting; Chronic Disease; Diuretics; Dyspnea, Paroxysmal; Furosemide; Heart Failure; Humans; Pu | 1972 |
Nondialytic management of chronic uremia.
Topics: Administration, Oral; Adult; Blood Urea Nitrogen; Chronic Disease; Creatinine; Diuresis; Diuretics; | 1973 |
[Effect of complex therapy on the electrolyte metabolism in patients with chronic hepatitis and liver cirrhosis].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Chronic Disease; Female; Furosemide; Hepatitis; Hu | 1973 |
[Effect of single administration of furosemide in patients with chronic liver disease].
Topics: Chronic Disease; Furosemide; Humans; Hyperglycemia; Liver Diseases | 1974 |
Glutamine transport in rat kidney mitochondria in metabolic acidosis.
Topics: Acetates; Acidosis; Ammonia; Animals; Biological Transport, Active; Carbon Radioisotopes; Chronic Di | 1974 |
The lazy respiratory center--or how to recognize a tired horse. Clinical conference in pulmonary disease from Northwestern University-McGaw Medical Center, Chicago.
Topics: Brain Diseases; Chemoreceptor Cells; Chronic Disease; Diagnosis, Differential; Diazepam; Digoxin; Fu | 1974 |
Contraction alkalosis during recovery of cardio-respiratory failure.
Topics: Acid-Base Equilibrium; Alkalosis; Bronchitis; Chronic Disease; Furosemide; Heart Failure; Humans; Wa | 1974 |
Proceedings: Effects of an acute diuresis on cardio-pulmonary function in oedematous chronic bronchitics.
Topics: Blood Pressure; Bronchitis; Cardiac Output; Chronic Disease; Diuresis; Furosemide; Heart; Heart Rate | 1974 |
[Intensive saluresis in the treatment of refractory edema due to chronic liver disease].
Topics: Blood Proteins; Chronic Disease; Diuresis; Edema; Electrolytes; Furosemide; Humans; Liver Cirrhosis; | 1972 |
[Amyloidosis in childhood].
Topics: Amyloidosis; Child; Chronic Disease; Encephalomyelitis; Furosemide; Humans; Male; Nephrotic Syndrome | 1971 |
[Aspects of urinary water-salt excretion in chronic nephropathies].
Topics: Chronic Disease; Furosemide; Glomerular Filtration Rate; Humans; Kidney; Kidney Failure, Chronic; Na | 1969 |
[Clinical study of the use of "Spirolang" 50].
Topics: Adult; Aged; Ascites; Chronic Disease; Digitalis Glycosides; Diuresis; Electrolytes; Ethacrynic Acid | 1971 |
Use of furosemide for evaluation of the urinary concentrating mechanism in chronic pyelonephritis.
Topics: Chronic Disease; Diabetes Complications; Diagnosis, Differential; Female; Furosemide; Glycosuria; Hu | 1968 |
[The long-term therapy of glomerulonephritis without renal insufficiency].
Topics: Azathioprine; Chronic Disease; Cortisone; Diet Therapy; Ethacrynic Acid; Furosemide; Glomerulonephri | 1968 |
Plasma ADH level in patients with chronic congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Blood Volume; Chronic Disease; Female; Furosemide; Heart Failure; Human | 1968 |
The correlation of fractional excretion of sodium and magnesium in the chronically diseased kidney of dog and man.
Topics: Animals; Blood Urea Nitrogen; Chronic Disease; Dogs; Female; Furosemide; Glomerular Filtration Rate; | 1969 |